ciprofloxacin has been researched along with Bacteremia in 307 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a randomized controlled trial involving 55 adult patients with enteric fever to compare ciprofloxacin and chloramphenicol." | 9.10 | Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever. ( Djokomoeljanto, R; Dolmans, WM; Gasem, MH; Keuter, M; Van Der Meer, JW; Van Der Ven-Jongekrijg, J, 2003) |
| "During a randomized study of clarithromycin plus clofazimine with or without ethambutol in patients with AIDS and Mycobacterium avium complex (MAC) bacteremia, eight participants received additional antimycobacterial drugs following the detection of a clarithromycin-resistant isolate (MIC, > 8 micrograms/mL)." | 9.09 | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. ( Dubé, MP; Havlir, DV; Kemper, CA; Leedom, JM; McCutchan, JA; Sattler, FR; See, D; Tilles, JG; Torriani, FJ, 1999) |
| "To compare, in patients with gram-negative bacteremia, a course of parenteral antibiotic therapy alone with initial parenteral therapy followed by oral ciprofloxacin in terms of the length of hospitalization, clinical effectiveness, toxicity, and cost." | 9.08 | Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis. ( Amodio-Groton, M; Briceland, LL; Madu, A; Madu, CN; McMaster, P; Miller, MH; Seligman, M, 1996) |
| " avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group)." | 9.08 | A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. ( Fanning, MM; Fong, IW; Gill, MJ; Lalonde, RG; Phillips, P; Rachlis, AR; Salit, I; Shafran, SD; Singer, J; Tsoukas, CM; Walmsley, SL; Zarowny, DP, 1996) |
| "A rapid reduction in symptoms and bacteremia can be achieved as early as week 2 of therapy using an oral regimen of rifampin, ethambutol, clofazimine, and ciprofloxacin." | 9.07 | Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. ( Bartok, AE; Chiu, J; Deresinski, SC; Feigal, DF; Kemper, CA; Leedom, JM; McCutchan, JA; Meng, TC; Nussbaum, J; Tilles, JG, 1992) |
| "A prospective, open and non-randomised clinical trial using a 7-day short course of oral ciprofloxacin 500 mg twice daily was conducted on 25 adult patients with bacteraemic enteric fever." | 9.07 | A 7-day course of ciprofloxacin for enteric fever. ( Allen, DM; Chew, SK; Lim, YS; Monteiro, EH, 1992) |
| " We compared the incidence of bacterial-related complications among 356 patients with multiple myeloma (MM) (n = 202) and lymphoma (n = 154) who underwent AHCT with (n = 177) or without (n = 179) ciprofloxacin prophylaxis between 03/2007 and 10/2012 and between 10/2012 and 07/2016, respectively, at a single centre." | 7.88 | Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. ( Bishara, J; Gurion, R; Herscovici, C; Lahav, M; Magen, H; Moshe, M; Naparstek, E; Pasvolsky, O; Peck, A; Raanani, P; Rozovski, U; Sela-Navon, M; Shargian, L; Vaxman, I; Vidal, L; Wolach, O; Yahav, D; Yeshurun, M, 2018) |
| "The aim of the study was to describe the incidence and type of bacterial infections associated with the use of ciprofloxacin prophylaxis as single agent in pediatric patients with acute myeloid leukemia (AML)." | 7.85 | Bacterial Infections in Children With Acute Myeloid Leukemia Receiving Ciprofloxacin Prophylaxis. ( Al Omar, S; Al Qasem, W; Anabtawi, N; Rihani, R, 2017) |
| " As far as we know, this is the first case of near-drowning-associated pneumonia with bacteremia caused by coinfection with methicillin-susceptible Staphylococcus aureus and Edwardsiella tarda in a healthy patient." | 7.83 | Near-drowning-associated pneumonia with bacteremia caused by coinfection with methicillin-susceptible Staphylococcus aureus and Edwardsiella tarda in a healthy white man: a case report. ( Cavallaro, MC; Chehter, N; Del Nero, LG; Marta, GN; Zambon, LS, 2016) |
| "The purpose of this study is to describe clinical characteristics of Salmonella bacteremia in adult patients and analyze ciprofloxacin-nonsusceptible isolates." | 7.81 | Clinical characteristics in adult patients with Salmonella bacteremia and analysis of ciprofloxacin-nonsusceptible isolates. ( Cheng, MW; Lee, CM; Lin, CC; Liu, CP; Shih, SC; Wang, NY; Weng, LC; Wu, AY, 2015) |
| "Ciprofloxacin (10 mg/kg, 12 hourly) was administered either 2 h before or up to 2 h after feeds to Kenyan children hospitalized with severe malnutrition." | 7.77 | Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation. ( Karisa, J; Kokwaro, G; Maitland, K; Muchohi, S; Muturi, A; Thomson, AH; Thuo, N; Ungphakorn, W, 2011) |
| " Daptomycin shows a high efficacy against CNS, and it could be useful for the treatment of primary bacteremia or catheter associated bacteremia." | 7.77 | Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia. ( Fajardo Olivares, M; Hidalgo Orozco, R; Robles Marcos, M; Rodríguez Garrido, S; Rodríguez-Vidigal, FF; Vera Tomé, A, 2011) |
| "We evaluated the clinical features of ciprofloxacin-resistant Proteus mirabilis bacteremia and risk factors for ciprofloxacin resistance." | 7.77 | Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Proteus mirabilis bacteremia. ( Chung, DR; Ha, YE; Joo, EJ; Kang, CI; Lee, NY; Peck, KR; Sohn, KM; Song, JH, 2011) |
| "The current results suggest that fluoroquinolone prophylaxis for patients with febrile neutropenia may be abandoned safely in areas with a high prevalence of ciprofloxacin-resistant enterobacteria." | 7.72 | Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. ( Dalmau, D; Estany, C; Estrada, C; Garau, J; Gomez, L; Marquez, M; Martí, JM; Xercavins, M, 2003) |
| "Fifty-five human immunodeficiency virus-infected patients with Salmonella bacteremia were studied to assess the rate of and causes for recurrence and to determine the influence on relapse of zidovudine, cotrimoxazole, and antimicrobial suppressive therapy according to the susceptibility of the isolates." | 7.70 | Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients. ( Calderon, C; Casado, JL; Frutos, B; Guerrero, A; Martinez-Beltran, J; Navas, E; Valdezate, S, 1999) |
| "An experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats was used to study the impact of the duration of infection on the bactericidal activity of ceftazidime, gentamicin and ciprofloxacin." | 7.68 | Impact of the duration of infection on the activity of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1991) |
| "A combination of clarithromycin, ciprofloxacin, and amikacin for the treatment of Mycobacterium avium-Mycobacterium intracellulare bacteremia was evaluated in 12 AIDS patients." | 7.68 | Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. ( Caccamo, F; de Lalla, F; Marone, P; Maserati, R; Nicolin, R; Rigoli, R; Scarpellini, P, 1992) |
| " Ciprofloxacin pharmacokinetic studies were carried out after the start of both regimens." | 6.75 | Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia. ( Aeinlang, N; Jaruratanasirikul, S; Jullangkoon, M; Saengsuwan, P, 2010) |
| "Bacteremia was documented in 33 patients (15." | 5.46 | Bacteremia during neutropenic episodes in children undergoing hematopoietic stem cell transplantation with ciprofloxacin and penicillin prophylaxis. ( Anurathapan, U; Choeyprasert, W; Hongeng, S; Pakakasama, S, 2017) |
| " After a pre-intervention period, in which cefepime was used as the initial agent for febrile neutropenia, 4 primary antibiotics, namely, piperacillin-tazobactam, ciprofloxacin, meropenem, and cefepime, were rotated at 1-month intervals over 20 months." | 5.17 | Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity. ( Akashi, K; Chong, Y; Ito, Y; Kamimura, T; Miyamoto, T; Shimoda, S; Shimono, N; Yakushiji, H, 2013) |
| "Compared to historical controls, patients in this study receiving prophylactic ciprofloxacin had a reduced rate and duration of hospitalization and incidence of Gram-negative bacteremia." | 5.11 | A pilot study of prophylactic ciprofloxacin during delayed intensification in children with acute lymphoblastic leukemia. ( Abbas, AA; Chedid, FD; Felimban, SK; Fryer, CJ; Khattab, TM; Yousef, AA, 2004) |
| "We performed a randomized controlled trial involving 55 adult patients with enteric fever to compare ciprofloxacin and chloramphenicol." | 5.10 | Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever. ( Djokomoeljanto, R; Dolmans, WM; Gasem, MH; Keuter, M; Van Der Meer, JW; Van Der Ven-Jongekrijg, J, 2003) |
| "The objective of this study was to characterize the prevalence and clinical significance of ciprofloxacin-resistant Escherichia coli in perianal swabs of patients with hematologic malignancies in a German university hospital." | 5.09 | Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. ( Baum, HV; Franz, U; Geiss, HK, 2000) |
| "In low-risk patients with cancer who have fever and granulocytopenia, oral therapy with ciprofloxacin plus amoxicillin-clavulanate is as effective as intravenous therapy." | 5.09 | Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Can ( Cometta, A; De Bock, R; Gaya, H; Kern, WV; Langenaeken, J; Paesmans, M, 1999) |
| "During a randomized study of clarithromycin plus clofazimine with or without ethambutol in patients with AIDS and Mycobacterium avium complex (MAC) bacteremia, eight participants received additional antimycobacterial drugs following the detection of a clarithromycin-resistant isolate (MIC, > 8 micrograms/mL)." | 5.09 | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. ( Dubé, MP; Havlir, DV; Kemper, CA; Leedom, JM; McCutchan, JA; Sattler, FR; See, D; Tilles, JG; Torriani, FJ, 1999) |
| " avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group)." | 5.08 | A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. ( Fanning, MM; Fong, IW; Gill, MJ; Lalonde, RG; Phillips, P; Rachlis, AR; Salit, I; Shafran, SD; Singer, J; Tsoukas, CM; Walmsley, SL; Zarowny, DP, 1996) |
| "A rapid reduction in symptoms and bacteremia can be achieved as early as week 2 of therapy using an oral regimen of rifampin, ethambutol, clofazimine, and ciprofloxacin." | 5.07 | Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. ( Bartok, AE; Chiu, J; Deresinski, SC; Feigal, DF; Kemper, CA; Leedom, JM; McCutchan, JA; Meng, TC; Nussbaum, J; Tilles, JG, 1992) |
| "A prospective, open and non-randomised clinical trial using a 7-day short course of oral ciprofloxacin 500 mg twice daily was conducted on 25 adult patients with bacteraemic enteric fever." | 5.07 | A 7-day course of ciprofloxacin for enteric fever. ( Allen, DM; Chew, SK; Lim, YS; Monteiro, EH, 1992) |
| " For treatment of uncomplicated VRE urinary tract infections, ciprofloxacin or nitrofurantoin can be used." | 4.98 | [Treatment of vancomycin-resistant enterococcal infections]. ( Holzknecht, BJ; Justesen, US; Lund, LC, 2018) |
| " For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal)." | 4.84 | [Bacterial infections in liver cirrhosis]. ( Farkas, A; Papp, M; Tornai, I; Udvardy, M, 2007) |
| "Prophylaxis with levofloxacin was associated with a lower incidence of febrile neutropenia and bacteremia when compared to ciprofloxacin in hematopoietic stem cell transplantation patients." | 3.91 | Ciprofloxacin vs. levofloxacin for prophylaxis in recipients of hematopoietic stem cell transplantation. ( Rambaran, KA; Seifert, CF, 2019) |
| " We compared the incidence of bacterial-related complications among 356 patients with multiple myeloma (MM) (n = 202) and lymphoma (n = 154) who underwent AHCT with (n = 177) or without (n = 179) ciprofloxacin prophylaxis between 03/2007 and 10/2012 and between 10/2012 and 07/2016, respectively, at a single centre." | 3.88 | Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. ( Bishara, J; Gurion, R; Herscovici, C; Lahav, M; Magen, H; Moshe, M; Naparstek, E; Pasvolsky, O; Peck, A; Raanani, P; Rozovski, U; Sela-Navon, M; Shargian, L; Vaxman, I; Vidal, L; Wolach, O; Yahav, D; Yeshurun, M, 2018) |
| "The aim of the study was to describe the incidence and type of bacterial infections associated with the use of ciprofloxacin prophylaxis as single agent in pediatric patients with acute myeloid leukemia (AML)." | 3.85 | Bacterial Infections in Children With Acute Myeloid Leukemia Receiving Ciprofloxacin Prophylaxis. ( Al Omar, S; Al Qasem, W; Anabtawi, N; Rihani, R, 2017) |
| "urinary tract infections." | 3.85 | In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital. ( Linasmita, P; Tantisiriwat, W, 2017) |
| "Bacteremia due to Pseudomonas aeruginosa resistant to carbapenems is a public health problem due to the limitations it places on therapeutic options, as well as the increased time patients must spend in hospital, costs and the risk of mortality." | 3.83 | Risk factors for hospital-acquired bacteremia due to carbapenem-resistant Pseudomonas aeruginosa in a Colombian hospital. ( Álvarez, C; Ardila, N; Ariza, B; Caro, MA; Gil, F; González, PF; Valderrama, SL, 2016) |
| " As far as we know, this is the first case of near-drowning-associated pneumonia with bacteremia caused by coinfection with methicillin-susceptible Staphylococcus aureus and Edwardsiella tarda in a healthy patient." | 3.83 | Near-drowning-associated pneumonia with bacteremia caused by coinfection with methicillin-susceptible Staphylococcus aureus and Edwardsiella tarda in a healthy white man: a case report. ( Cavallaro, MC; Chehter, N; Del Nero, LG; Marta, GN; Zambon, LS, 2016) |
| "The purpose of this study is to describe clinical characteristics of Salmonella bacteremia in adult patients and analyze ciprofloxacin-nonsusceptible isolates." | 3.81 | Clinical characteristics in adult patients with Salmonella bacteremia and analysis of ciprofloxacin-nonsusceptible isolates. ( Cheng, MW; Lee, CM; Lin, CC; Liu, CP; Shih, SC; Wang, NY; Weng, LC; Wu, AY, 2015) |
| "We analyzed a cohort of 329 episodes of chemotherapy-induced neutropenia in adults, and compared two periods: 2005 (period 1, no prophylaxis, n=110) and 2006-2008 (period 2, ciprofloxacin prophylaxis, n=219)." | 3.79 | Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. ( Garnica, M; Maiolino, A; Moreira, BM; Nouér, SA; Nucci, M; Pellegrino, FL, 2013) |
| " We conducted a prospective study to know the incidence of Campylobacter jejuni bacteremia in pediatric patients and its susceptibility to erythromycin and ciprofloxacin." | 3.79 | [Incidence and susceptibility of Campylobacter jejuni in pediatric patients: involvement in bacteremia]. ( Alonso-Sanz, M; González-Abad, MJ, 2013) |
| "Discordant empirical therapy, mostly with ciprofloxacin, leads to worse early clinical response and longer hospital stay than concordant therapy in community-acquired bacteremic acute pyelonephritis, although it does not affect on overall mortality or clinical cure rate." | 3.77 | Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. ( Chung, DR; Kim, Y; Lee, SS, 2011) |
| "We evaluated the clinical features of ciprofloxacin-resistant Proteus mirabilis bacteremia and risk factors for ciprofloxacin resistance." | 3.77 | Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Proteus mirabilis bacteremia. ( Chung, DR; Ha, YE; Joo, EJ; Kang, CI; Lee, NY; Peck, KR; Sohn, KM; Song, JH, 2011) |
| " Daptomycin shows a high efficacy against CNS, and it could be useful for the treatment of primary bacteremia or catheter associated bacteremia." | 3.77 | Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia. ( Fajardo Olivares, M; Hidalgo Orozco, R; Robles Marcos, M; Rodríguez Garrido, S; Rodríguez-Vidigal, FF; Vera Tomé, A, 2011) |
| "Ciprofloxacin (10 mg/kg, 12 hourly) was administered either 2 h before or up to 2 h after feeds to Kenyan children hospitalized with severe malnutrition." | 3.77 | Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation. ( Karisa, J; Kokwaro, G; Maitland, K; Muchohi, S; Muturi, A; Thomson, AH; Thuo, N; Ungphakorn, W, 2011) |
| "In vitro activities of colistin and other drugs were tested against 221 Klebsiella pneumoniae isolates that were collected between 2006 and 2007 in nine tertiary care South Korean hospitals from patients with bacteremia." | 3.76 | Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. ( Chung, DR; Ko, KS; Peck, KR; Son, JS; Song, JH; Suh, JY, 2010) |
| "This study seeks to determine the incidence of vancomycin-resistant enterococci (VRE) infection in high-risk neutropenic fever patients colonized with VRE and to determine patient characteristics associated with VRE infection." | 3.76 | Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. ( Bossaer, JB; Garrett-Mayer, E; Hall, PD, 2010) |
| "P aeruginosa bacteremic isolates from patients who have been exposed to ciprofloxacin during the 30 days prior to the development of bacteremia have an increased risk of being resistant to ceftazidime, imipenem, meropenem, piperacillin-tazobactam, or ciprofloxacin and to have multidrug resistance." | 3.75 | Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. ( Almela, M; López, J; López-Dupla, M; Marco, F; Martínez, JA; Mensa, J; Olona, M; Soriano, A; Vidal, F, 2009) |
| "We present a case of recurrent infection (infective spondilitis, psoas abscess, and bacteraemia) caused by a single strain of cefotaxime- and ciprofloxacin-resistant and bla(CMY-2)-containing Salmonella enterica serotype choleraesuis during a 4-month period in a patient with uremia." | 3.73 | Recurrent infections caused by cefotaxime- and ciprofloxacin-resistant Salmonella enterica serotype choleraesuis treated successfully with imipenem. ( Guo, SM; Hsueh, PR; Jean, SS; Lee, YT, 2005) |
| "To evaluate the clinical features of ciprofloxacin-resistant Enterobacter bacteremia and to examine the risk factors for ciprofloxacin resistance in Enterobacter species isolates causing bacteremia." | 3.73 | Clinical epidemiology of ciprofloxacin resistance and its relationship to broad-spectrum cephalosporin resistance in bloodstream infections caused by Enterobacter species. ( Choe, KW; Kang, CI; Kim, EC; Kim, HB; Kim, SH; Lee, KD; Oh, MD; Park, WB, 2005) |
| "We evaluated the virulence of Pseudomonas aeruginosa carrying bla(IMP), a metallo-beta-lactamase gene, and the efficacy of ceftazidime, imipenem-cilastatin, and ciprofloxacin in the endogenous bacteremia model." | 3.72 | Virulence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in vitro and in vivo. ( Aoki, S; Gotoh, N; Hirakata, Y; Kamihira, S; Kohno, S; Kondoh, A; Miyazaki, Y; Tomono, K; Yamada, Y; Yanagihara, K, 2004) |
| "The current results suggest that fluoroquinolone prophylaxis for patients with febrile neutropenia may be abandoned safely in areas with a high prevalence of ciprofloxacin-resistant enterobacteria." | 3.72 | Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. ( Dalmau, D; Estany, C; Estrada, C; Garau, J; Gomez, L; Marquez, M; Martí, JM; Xercavins, M, 2003) |
| " Despite prolonged bacteremia, the response to long-term therapy with ciprofloxacin and rifampin was excellent." | 3.70 | Helicobacter cinaedi septic arthritis and bacteremia in an immunocompetent patient. ( Boussougant, Y; Lasry, S; Marais, A; Pouchot, J; Simon, J; Vinceneux, P, 2000) |
| " sordellii ischio-rectal abscess with rapidly fatal septicaemia is described which complicated ultrasound-guided transrectal biopsy of the prostate, despite ciprofloxacin prophylaxis." | 3.70 | Fatal Clostridium sordellii ischio-rectal abscess with septicaemia complicating ultrasound-guided transrectal prostate biopsy. ( Borer, A; Buskila, D; Gilad, J; Riesenberg, K; Schlaeffer, F; Sikuler, E, 1999) |
| "Fifty-five human immunodeficiency virus-infected patients with Salmonella bacteremia were studied to assess the rate of and causes for recurrence and to determine the influence on relapse of zidovudine, cotrimoxazole, and antimicrobial suppressive therapy according to the susceptibility of the isolates." | 3.70 | Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients. ( Calderon, C; Casado, JL; Frutos, B; Guerrero, A; Martinez-Beltran, J; Navas, E; Valdezate, S, 1999) |
| "The susceptibility of clinical isolates of methicillin-susceptible and -resistant staphylococci from cancer patients with central venous catheter bacteremia to quinupristin/dalfopristin, a semisynthetic streptogramin, was determined in vitro." | 3.69 | In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections. ( Garcia, R; Raad, I, 1996) |
| "From 1988 to 1992, 27 of 855 cases of Escherichia coli bacteremia in nonneutropenic adult patients observed at our hospital were due to ciprofloxacin-resistant (CIPRO-R) strains." | 3.69 | Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. ( Albareda, JM; Ariza, J; Pallares, R; Peña, C; Pujol, M; Tubau, F, 1995) |
| "The effect of oral therapy with three quinolones (ofloxacin, ciprofloxacin, and pefloxacin) in the prevention of postirradiation bacteremia and mortality was tested in B6D2F1 mice given 9." | 3.68 | Quinolone therapy in the prevention of mortality after irradiation. ( Brook, I; Elliott, TB, 1991) |
| "An experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats was used to study the impact of the duration of infection on the bactericidal activity of ceftazidime, gentamicin and ciprofloxacin." | 3.68 | Impact of the duration of infection on the activity of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1991) |
| "A combination of clarithromycin, ciprofloxacin, and amikacin for the treatment of Mycobacterium avium-Mycobacterium intracellulare bacteremia was evaluated in 12 AIDS patients." | 3.68 | Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. ( Caccamo, F; de Lalla, F; Marone, P; Maserati, R; Nicolin, R; Rigoli, R; Scarpellini, P, 1992) |
| " Blood and ultrafiltrate samples were collected and assayed for ciprofloxacin by High Performance Liquid Chromatography (HPLC) to calculate the model independent pharmacokinetic parameters; total body clearance (TBC), half-life (t1/2) and volume of distribution (Vd)." | 2.76 | An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. ( Corrigan, OI; D'Arcy, DM; Deegan, C; Donnelly, MB; Gowing, CM; Spooner, AM, 2011) |
| "Amikacin was well tolerated." | 2.69 | A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team. ( Barber, TW; Currier, J; Ellner, JJ; Hafner, R; Hojczyk, P; Hooton, TM; Jacobs, MR; Limjoco, M; Parenti, DM; Powderly, WG; Simpson, G; van der Horst, C; Williams, PL, 1998) |
| "coli bacteremia were due to QREC." | 2.69 | Emergence and dissemination of quinolone-resistant Escherichia coli in the community. ( Coll, I; Garau, J; Gómez-Vera, JR; Llovet, T; Rodríguez-Carballeira, M; Ruíz-Bremón, A; Vidal, D; Xercavins, M, 1999) |
| " No dosage modifications were made in patients with renal impairment." | 2.68 | The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. ( Hedges, AJ; Jones, EM; Lovering, AM; MacGowan, AP; McMullin, CM; Reeves, DS; White, LO, 1997) |
| "Also for lower respiratory tract infections (LTRI) the clinical and bacteriological responses were quite similar, although relatively more failures occurred in CF treated patients with LRTI caused by pneumococci." | 2.67 | Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety. ( Andersen, BM; Bergan, T; Brubakk, O; Bruun, JN; Døskeland, B; Hellum, KB; Hopen, G; Kalager, T; Rahm, V; von der Lippe, E, 1992) |
| "Ciprofloxacin was therefore superior to the other two fluoroquinolones in preventing infections due to Gram-negative bacteria in this population of neutropenic patients." | 2.67 | Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies. ( Accorsi, P; Betti, S; D'Antonio, D; Dell'Isola, M; Favalli, C; Fioritoni, G; Iacone, A; Parruti, G; Piccolomini, R; Quaglietta, AM, 1994) |
| "cinaedi bacteremia have been published; most cases have presented as a nonspecific febrile illness in homosexual men infected with the human immunodeficiency virus (HIV)." | 2.39 | Multifocal cellulitis and monoarticular arthritis as manifestations of Helicobacter cinaedi bacteremia. ( Burman, WJ; Cohn, DL; Reves, RR; Wilson, ML, 1995) |
| "Ciprofloxacin was the most prescribed oral antibiotic (53%)." | 1.72 | Intravenous to oral transition of antibiotics for gram-negative bloodstream infection at a University hospital in Thailand: Clinical outcomes and predictors of treatment failure. ( Gross, AE; Nakaranurack, C; Pradubkham, T; Suwanpimolkul, G, 2022) |
| "Bacteremia-induced sepsis is a leading cause of mortality in intensive care units." | 1.62 | Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice. ( Alalaiwe, A; Dai, YS; Fang, JY; Liao, CC; Liu, FC; Yang, SC; Yu, HP, 2021) |
| "Bacteremia was documented in 33 patients (15." | 1.46 | Bacteremia during neutropenic episodes in children undergoing hematopoietic stem cell transplantation with ciprofloxacin and penicillin prophylaxis. ( Anurathapan, U; Choeyprasert, W; Hongeng, S; Pakakasama, S, 2017) |
| "Methicillin resistance was evaluated with the cefoxitin disk test." | 1.42 | Antibiotic Susceptibility of Biofilm Cells and Molecular Characterisation of Staphylococcus hominis Isolates from Blood. ( Camacho-Ortiz, A; Casillas-Vega, N; Garza-González, E; González, GM; Llaca-Díaz, J; Mendoza-Olazarán, S; Morfín-Otero, R; Rodríguez-Noriega, E; Villarreal-Treviño, L, 2015) |
| "Clarithromycin and rifampin were shown to be effective only as a postexposure prophylactic treatment but failed to treat the systemic (bacteremic) phase of anthrax." | 1.42 | Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits. ( Altboum, Z; Bar-David, E; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S, 2015) |
| "Intensifying treatment for pediatric acute myeloid leukemia (AML) has improved survival, with infections now being a leading cause of morbidity." | 1.42 | Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia. ( Felsenstein, S; Fu, C; Hoffman, JA; Orgel, E; Rushing, T, 2015) |
| "Ciprofloxacin alone was associated with significantly more infections than ciprofloxacin plus an additional agent (P = 0." | 1.42 | Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy. ( Gupta, K; Lerner, L; Marino, K; Orlando, R; Parlee, A; Strymish, J, 2015) |
| "The pefloxacin disk assay was approved and implemented by EUCAST (in 2014) and CLSI (in 2015)." | 1.42 | Development of a Pefloxacin Disk Diffusion Method for Detection of Fluoroquinolone-Resistant Salmonella enterica. ( Åhman, J; Kahlmeter, G; Matuschek, E; Petersen, A; Sjölund-Karlsson, M; Skov, R; Stegger, M; Torpdahl, M, 2015) |
| "P." | 1.42 | Bloodstream bacterial infection among outpatient children with acute febrile illness in north-eastern Tanzania. ( Butichi, A; Lemnge, M; Lushino, P; Lusingu, J; Mahende, C; Mmbando, B; Ngasala, B; Premji, Z, 2015) |
| "The aim of this work was to define the optimal dosage (OD) of ciprofloxacin in order to prevent the emergence of bacterial resistance of Pseudomonas aeruginosa in a geriatric population with a bloodstream infection." | 1.42 | Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study. ( Bourguignon, L; Cazaubon, Y; Ducher, M; Goutelle, S; Maire, P; Martin, O, 2015) |
| "When bacteremia is significant, it occurs mostly in patients with hematologic malignancies and is predominantly catheter-related." | 1.42 | Staphylococcus saprophyticus bacteremia after ESWL in an immunocompetent woman. ( Boel, A; De Beenhouwer, H; Hofmans, M; Van Vaerenbergh, K, 2015) |
| "One patient developed Fusarium infection." | 1.40 | Bloodstream and central line isolates from hematopoietic stem cell transplant recipients: data from a developing country. ( Adil, SN; Ali, N; Shaikh, MU, 2014) |
| "Intensive chemotherapy for pediatric acute myeloid leukemia incurs the risk of infectious complications, but the benefits of antibiotic prophylaxis remain unclear." | 1.40 | Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. ( Avutu, V; Cao, X; Flynn, PM; Gaur, AH; Hayden, RT; Howard, SC; Inaba, H; Marszal, LN; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE, 2014) |
| "Typhoid fever is caused by Salmonella enterica serovar Typhi, a major public health concern in developing countries." | 1.38 | Antimicrobial resistance trends in blood culture positive Salmonella Typhi isolates from Pondicherry, India, 2005-2009. ( Goessens, WH; Harish, BN; Hays, JP; Khan, MA; Menezes, GA, 2012) |
| "However the number of septic arthritis cases due to S." | 1.38 | [Septic arthritis of hip due to Salmonella Typhi in a patient with multiple sclerosis]. ( Altay, T; Avcı, M; Coşkuner, SA; Havuk, A; Olut, AI; Ozgenç, O; Ozsu Caymaz, S, 2012) |
| "At this time he remains asymptomatic." | 1.37 | Melioidosis presenting as sepsis syndrome: a case report. ( Caldera, J; Calvo, A; Figuera, M; Gómez, M; Guevara, RN; Khalil, R; Landaeta, ME; Morón, M; Nuñez, MJ; Palavecino, S; Redondo, MC; Ríos, H; Rivera, R; Vitelli, J, 2011) |
| "We report here the first case of C." | 1.36 | Spondylodiscitis and an aortic aneurysm due to Campylobacter coli. ( Bournet, BS; Cattoen, C; Dehecq, C; Garnier, LD; Lemaire, X; Senneville, E; Yazdanpanah, Y, 2010) |
| "Ciprofloxacin resistance was observed only in hospital strains." | 1.35 | Bacillus cereus nosocomial infection from reused towels in Japan. ( Baranovich, T; Dohmae, S; Higuchi, W; Isobe, H; Itoh, M; Kobayashi, S; Okubo, T; Takano, T; Tanabe, Y; Uchiyama, M; Yamamoto, T, 2008) |
| "Ciprofloxacin resistance was more frequent in children who shared an environment with adults who were receiving ciprofloxacin prophylaxis." | 1.33 | Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres. ( Castagnola, E; Caviglia, I; Giona, F; Girmenia, C; Haupt, R; Micozzi, A; Parodi, S; Testi, AM, 2005) |
| "An 81-year-old man developed septic arthritis and bacteraemia with Aeromonas veronii biovar sobria." | 1.33 | Aeromonas veronii biovar sobria bacteraemia with septic arthritis confirmed by 16S rDNA PCR in an immunocompetent adult. ( Enoch, DA; Harris, KA; Karas, JA; Roberts, MTM, 2006) |
| "coli bacteremia have not changed, yet the mortality was lower in our series." | 1.32 | [Bacteremia due to Escherichia coli: epidemiological analysis and sensitivity to antibiotics in a county hospital]. ( García-Somoza, D; Gudiol, F; Javaloyas, M, 2003) |
| "Severe thrombocytopenia is a life-threatening condition." | 1.32 | Cardiobacterium hominis endocarditis associated with very severe thrombocytopenia and platelet autoantibodies. ( Arnold, DM; Christjanson, L; Smaill, F; Walker, I; Warkentin, TE, 2004) |
| "To investigate the adverse effects of ciprofloxacin administered to neonates with sepsis on the hematologic indices, the hepatic and renal function and the joints and growth at 1 year follow-up." | 1.32 | Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year. ( Agakidis, C; Drossou-Agakidou, V; Kremenopoulos, G; Nikolaides, N; Papakyriakidou-Koliouska, P; Roilides, E; Sarafidis, K, 2004) |
| "A 73-year-old woman with liver cirrhosis who developed H." | 1.30 | Haemophilus aphrophilus bacteraemia complicated with vertebral osteomyelitis and spinal epidural abscess in a patient with liver cirrhosis. ( Chang, SC; Chen, YC; Fang, CT; Hsieh, WC; Hsueh, PR; Hung, CC; Luh, KT, 1997) |
| " The dosing regimen of each drug that yielded serum levels in mice which mimic human therapeutic concentrations of the drugs, were designed." | 1.30 | Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ( Bui, KQ; Nicolau, DP; Nightingale, CH; Onyeji, CO; Owens, RC; Quintiliani, R, 1999) |
| " Test fluoroquinolones were administered orally at 1 h (single dose) or at 1 and 3 h (divided dose) postinfection, with 10 infected mice used for each of six concentrations of each fluoroquinolone tested (1 to 40 mg/kg of body weight) in each dosing regimen." | 1.29 | In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia. ( Amaratunga, DJ; Barrett, JF; Frosco, MB; Yagel, SK, 1996) |
| "No bacteremia was noted." | 1.29 | Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue. ( Brehm, T; Gollard, R; McMillan, R; Meisenberg, B; Miller, W, 1996) |
| " Rats were also treated with E5 or B55 in combination with a suboptimal dose of ciprofloxacin at fever onset and again 24 h later." | 1.29 | Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis. ( Opal, SM; Palardy, JE; Romulo, RL, 1993) |
| "A total of 16 cases of salmonella mycotic aneurysms occurred." | 1.29 | Mycotic aneurysm due to non-typhi salmonella: report of 16 cases. ( Chen, YS; Cheng, DL; Liu, YC; Wang, JH; Wann, SR; Yen, MY, 1996) |
| "Penicillin G prophylaxis was associated with an increased incidence of fever of unknown origin and more frequent isolation of aerobic gram-negative bacteria in surveillance cultures." | 1.29 | Evaluation of penicillin G in the prevention of streptococcal septicaemia in patients with acute myeloid leukaemia undergoing cytotoxic chemotherapy. ( de Jong, M; de Jong, P; Kuijper, E; van der Lelie, J, 1993) |
| "We describe a case of infectious arthritis caused by C." | 1.29 | Campylobacter jejuni arthritis in secondary amyloidosis. ( Markusse, HM; Simon, CH, 1995) |
| "Three cases of recrudescence and relapse of Neisseria meningitidis group B meningitis and septicaemia are reported." | 1.29 | Recrudescence and relapse of meningococcal meningitis and septicaemia. ( Nielsen, PE; Thelle, T; Tvede, M, 1995) |
| "Neutropenia was less severe (P < 0." | 1.29 | Prevention of bacteraemia by systemic ciprofloxacin treatment in rat cytomegalovirus-infected immunocompromised rats. ( Bruggeman, CA; Stals, FS; vd Bogaard, AE, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 81 (26.38) | 18.2507 |
| 2000's | 97 (31.60) | 29.6817 |
| 2010's | 114 (37.13) | 24.3611 |
| 2020's | 15 (4.89) | 2.80 |
| Authors | Studies |
|---|---|
| Tumbarello, M | 2 |
| Sanguinetti, M | 2 |
| Montuori, E | 1 |
| Trecarichi, EM | 2 |
| Posteraro, B | 1 |
| Fiori, B | 2 |
| Citton, R | 1 |
| D'Inzeo, T | 2 |
| Fadda, G | 2 |
| Cauda, R | 2 |
| Spanu, T | 2 |
| Daikos, GL | 1 |
| Kosmidis, C | 1 |
| Tassios, PT | 1 |
| Petrikkos, G | 2 |
| Vasilakopoulou, A | 1 |
| Psychogiou, M | 1 |
| Stefanou, I | 1 |
| Avlami, A | 1 |
| Katsilambros, N | 1 |
| Strahilevitz, J | 1 |
| Engelstein, D | 1 |
| Adler, A | 1 |
| Temper, V | 1 |
| Moses, AE | 1 |
| Block, C | 1 |
| Robicsek, A | 1 |
| Hocquet, D | 1 |
| Berthelot, P | 1 |
| Roussel-Delvallez, M | 1 |
| Favre, R | 1 |
| Jeannot, K | 1 |
| Bajolet, O | 1 |
| Marty, N | 1 |
| Grattard, F | 1 |
| Mariani-Kurkdjian, P | 1 |
| Bingen, E | 1 |
| Husson, MO | 1 |
| Couetdic, G | 1 |
| Plésiat, P | 1 |
| Sali, M | 1 |
| Leone, F | 1 |
| Rossi, M | 1 |
| De Pascale, G | 1 |
| Zhanel, GG | 1 |
| Karlowsky, JA | 1 |
| Suh, JY | 1 |
| Son, JS | 1 |
| Chung, DR | 5 |
| Peck, KR | 5 |
| Ko, KS | 2 |
| Song, JH | 4 |
| Lee, CH | 2 |
| Su, LH | 2 |
| Li, CC | 1 |
| Chien, CC | 1 |
| Tang, YF | 1 |
| Liu, JW | 1 |
| Yeh, TC | 1 |
| Hou, JY | 1 |
| Huang, TH | 1 |
| Lu, CH | 1 |
| Sun, FJ | 1 |
| Huang, HM | 1 |
| Liu, HC | 1 |
| Teitelbaum, D | 1 |
| Elligsen, M | 1 |
| Katz, K | 1 |
| Lam, PW | 1 |
| Lo, J | 1 |
| MacFadden, D | 1 |
| Vermeiren, C | 1 |
| Daneman, N | 1 |
| Coombs, GW | 4 |
| Daley, DA | 4 |
| Yee, NWT | 1 |
| Shoby, P | 4 |
| Mowlaboccus, S | 4 |
| Pradubkham, T | 1 |
| Suwanpimolkul, G | 1 |
| Gross, AE | 1 |
| Nakaranurack, C | 1 |
| Pal, E | 1 |
| Štrumbelj, I | 1 |
| Kišek, TC | 1 |
| Kolenc, M | 1 |
| Pirš, M | 1 |
| Rus, KR | 1 |
| Triglav, T | 1 |
| Avšič-Županc, T | 1 |
| Nielsen, RT | 1 |
| Andersen, CØ | 1 |
| Schønheyder, HC | 1 |
| Petersen, JH | 1 |
| Knudsen, JD | 1 |
| Jarløv, JO | 1 |
| Norredam, M | 1 |
| Garcia, C | 1 |
| Hinostroza, N | 1 |
| Astocondor, L | 1 |
| Ochoa, T | 1 |
| Jacobs, J | 3 |
| Axelsson, C | 1 |
| Rehnstam-Holm, AS | 1 |
| Nilson, B | 1 |
| Reed, TAN | 1 |
| Watson, G | 1 |
| Kheng, C | 1 |
| Tan, P | 1 |
| Roberts, T | 1 |
| Ling, CL | 1 |
| Miliya, T | 1 |
| Turner, P | 2 |
| Oliver, AC | 1 |
| Riva, E | 1 |
| Mosquera, R | 1 |
| Galeano, S | 1 |
| Pierri, S | 1 |
| Bello, L | 1 |
| Caneiro, A | 1 |
| Gai, R | 1 |
| Miller, A | 1 |
| Muxi, P | 1 |
| Tack, B | 1 |
| Phoba, MF | 2 |
| Barbé, B | 2 |
| Kalonji, LM | 2 |
| Hardy, L | 1 |
| Van Puyvelde, S | 1 |
| Ingelbeen, B | 1 |
| Falay, D | 2 |
| Ngonda, D | 1 |
| van der Sande, MAB | 1 |
| Deborggraeve, S | 1 |
| Lunguya, O | 2 |
| Maurer, AK | 1 |
| Li, S | 1 |
| Hunter, BD | 1 |
| Luk, SO | 1 |
| O'Donnell, SE | 1 |
| Dey, BR | 1 |
| El-Jawahri, A | 1 |
| Frigault, MJ | 1 |
| McAfee, S | 1 |
| O'Donnell, PV | 1 |
| Spitzer, TR | 1 |
| Chen, YB | 1 |
| DeFilipp, Z | 1 |
| Liao, CC | 1 |
| Yu, HP | 1 |
| Yang, SC | 1 |
| Alalaiwe, A | 1 |
| Dai, YS | 1 |
| Liu, FC | 1 |
| Fang, JY | 1 |
| Valcarcel, B | 1 |
| De-la-Cruz-Ku, G | 1 |
| Malpica, L | 1 |
| Enriquez-Vera, D | 1 |
| Arı, A | 1 |
| Ilgın Olut, A | 1 |
| Ay, B | 1 |
| Tosun, S | 1 |
| Zencir, M | 1 |
| Çayıröz, MU | 1 |
| Conn, JR | 1 |
| Catchpoole, EM | 1 |
| Runnegar, N | 1 |
| Mapp, SJ | 1 |
| Markey, KA | 1 |
| Chen, CH | 1 |
| Lin, CH | 1 |
| Lin, JS | 1 |
| Corbella, M | 1 |
| Brandolini, M | 1 |
| Cambieri, P | 1 |
| Decembrino, N | 1 |
| Pagani, M | 1 |
| Bottazzi, A | 1 |
| Muzzi, A | 1 |
| Zecca, M | 1 |
| Mariani, B | 1 |
| Marone, P | 3 |
| Jean, SS | 2 |
| Hsieh, TC | 1 |
| Ning, YZ | 1 |
| Hsueh, PR | 9 |
| Mohsin, J | 1 |
| Pál, T | 1 |
| Petersen, JE | 1 |
| Darwish, D | 1 |
| Ghazawi, A | 1 |
| Ashraf, T | 1 |
| Sonnevend, A | 1 |
| Matsuura, N | 1 |
| Miyoshi, M | 1 |
| Doi, N | 1 |
| Yagi, S | 1 |
| Aradono, E | 1 |
| Imamura, T | 1 |
| Koga, R | 1 |
| Heather, CS | 1 |
| Maley, M | 1 |
| Shaharir, SS | 1 |
| Sulaiman Sahari, N | 1 |
| Mohamed Fuad, Z | 1 |
| Zukiman, WZHW | 1 |
| Mohd Yusof, NH | 1 |
| Sulong, A | 1 |
| Periasamy, P | 1 |
| Ko, JH | 1 |
| Lee, NR | 1 |
| Joo, EJ | 2 |
| Moon, SY | 1 |
| Choi, JK | 1 |
| Park, DA | 1 |
| Yeshurun, M | 1 |
| Vaxman, I | 1 |
| Shargian, L | 1 |
| Yahav, D | 1 |
| Bishara, J | 2 |
| Pasvolsky, O | 1 |
| Wolach, O | 1 |
| Lahav, M | 1 |
| Gurion, R | 1 |
| Magen, H | 1 |
| Vidal, L | 1 |
| Herscovici, C | 1 |
| Peck, A | 1 |
| Moshe, M | 1 |
| Sela-Navon, M | 1 |
| Naparstek, E | 1 |
| Raanani, P | 1 |
| Rozovski, U | 1 |
| Roberts, MJ | 1 |
| Scott, S | 1 |
| Harris, PN | 1 |
| Naber, K | 1 |
| Wagenlehner, FME | 1 |
| Doi, SAR | 1 |
| Hemarajata, P | 1 |
| Amick, T | 1 |
| Yang, S | 1 |
| Gregson, A | 1 |
| Holzmeyer, C | 1 |
| Bush, K | 1 |
| Humphries, RM | 1 |
| Wu, PF | 1 |
| Lin, YT | 1 |
| Wang, FD | 1 |
| Yang, TC | 1 |
| Fung, CP | 1 |
| Lund, LC | 1 |
| Holzknecht, BJ | 1 |
| Justesen, US | 1 |
| Tantisiriwat, W | 1 |
| Linasmita, P | 1 |
| Rambaran, KA | 1 |
| Seifert, CF | 1 |
| Kanzawa, Y | 1 |
| Ishimaru, N | 1 |
| Seto, H | 1 |
| Tsutsumi, T | 1 |
| Kinami, S | 1 |
| Nagiah, S | 1 |
| Badbess, R | 1 |
| Villaverde González, S | 1 |
| Eugenieva Marinova, F | 1 |
| Rasines Rodríguez, A | 1 |
| Orden Martínez, B | 1 |
| Golmayo Gaztelu, L | 1 |
| Saez Nieto, JA | 1 |
| Cilleruelo Ortega, MJ | 1 |
| Thurber, KM | 1 |
| Arnold, JR | 1 |
| Narayanan, PP | 1 |
| Dierkhising, RA | 1 |
| Sampathkumar, P | 1 |
| Harch, SAJ | 1 |
| Jennison, AV | 1 |
| Bastian, I | 1 |
| Josa Laorden, C | 1 |
| Gómez del Valle, C | 1 |
| Bucar Barjud, M | 1 |
| Amores Arriaga, MB | 1 |
| Torralba Cabeza, MA | 1 |
| Pérez Calvo, JI | 1 |
| González-Abad, MJ | 1 |
| Alonso-Sanz, M | 1 |
| Garnica, M | 1 |
| Nouér, SA | 1 |
| Pellegrino, FL | 1 |
| Moreira, BM | 1 |
| Maiolino, A | 1 |
| Nucci, M | 1 |
| Gopal Rao, G | 1 |
| Batura, D | 1 |
| Alhashash, F | 1 |
| Weston, V | 1 |
| Diggle, M | 1 |
| McNally, A | 1 |
| De Rosa, FG | 1 |
| Motta, I | 1 |
| Audisio, E | 1 |
| Frairia, C | 1 |
| Busca, A | 1 |
| Di Perri, G | 1 |
| Marmont, F | 1 |
| Fatima, A | 1 |
| Afridi, FI | 1 |
| Qureshi, A | 1 |
| Farooqi, BJ | 1 |
| Hussain, A | 1 |
| Tai, KP | 1 |
| Kamdar, K | 1 |
| Yamaki, J | 1 |
| Le, VV | 1 |
| Tran, D | 1 |
| Tran, P | 1 |
| Selsted, ME | 1 |
| Ouellette, AJ | 1 |
| Wong-Beringer, A | 1 |
| van der Vusse, ML | 1 |
| van Son, WJ | 1 |
| Ott, A | 1 |
| Manson, W | 1 |
| Blennow, O | 1 |
| Ljungman, P | 1 |
| Sparrelid, E | 1 |
| Mattsson, J | 1 |
| Remberger, M | 1 |
| Ali, N | 1 |
| Adil, SN | 1 |
| Shaikh, MU | 1 |
| Kim, J | 1 |
| Kang, CI | 7 |
| Baek, JY | 1 |
| Cho, SY | 3 |
| Kim, SH | 5 |
| Inaba, H | 1 |
| Gaur, AH | 1 |
| Cao, X | 1 |
| Flynn, PM | 2 |
| Pounds, SB | 1 |
| Avutu, V | 1 |
| Marszal, LN | 1 |
| Howard, SC | 1 |
| Pui, CH | 1 |
| Ribeiro, RC | 1 |
| Hayden, RT | 2 |
| Rubnitz, JE | 1 |
| Traglia, GM | 1 |
| Almuzara, M | 1 |
| Vilacoba, E | 1 |
| Tuduri, A | 1 |
| Neumann, G | 1 |
| Pallone, E | 1 |
| Centrón, D | 1 |
| Ramírez, MS | 1 |
| Mahmood, A | 1 |
| Al Hakawati, MI | 1 |
| de Miguel-Martinez, I | 1 |
| Lorenzo-Garde, L | 1 |
| Cañas-Hernandez, F | 1 |
| Wong, PH | 1 |
| von Krosigk, M | 1 |
| Roscoe, DL | 1 |
| Lau, TT | 1 |
| Yousefi, M | 1 |
| Bowie, WR | 1 |
| Heidari Bateni, Z | 1 |
| Shahrokh, H | 1 |
| Salimi, H | 1 |
| Safari, H | 1 |
| Tabatabai, M | 1 |
| Saedi, D | 1 |
| Giacobbe, DR | 1 |
| Del Bono, V | 1 |
| Coppo, E | 1 |
| Marchese, A | 1 |
| Viscoli, C | 1 |
| Hofmans, M | 1 |
| Boel, A | 1 |
| Van Vaerenbergh, K | 1 |
| De Beenhouwer, H | 1 |
| Cha, MK | 1 |
| Wi, YM | 1 |
| Ha, YE | 2 |
| Lee, NY | 4 |
| Felsenstein, S | 1 |
| Orgel, E | 1 |
| Rushing, T | 1 |
| Fu, C | 1 |
| Hoffman, JA | 1 |
| Forsblom, E | 1 |
| Ruotsalainen, E | 1 |
| Järvinen, A | 1 |
| Mahende, C | 1 |
| Ngasala, B | 1 |
| Lusingu, J | 1 |
| Butichi, A | 1 |
| Lushino, P | 1 |
| Lemnge, M | 1 |
| Mmbando, B | 1 |
| Premji, Z | 1 |
| Su, TY | 1 |
| Ye, JJ | 1 |
| Hsu, PC | 1 |
| Kuo, AJ | 1 |
| Chia, JH | 1 |
| Lee, MH | 2 |
| Skov, R | 1 |
| Matuschek, E | 1 |
| Sjölund-Karlsson, M | 1 |
| Åhman, J | 1 |
| Petersen, A | 1 |
| Stegger, M | 1 |
| Torpdahl, M | 1 |
| Kahlmeter, G | 1 |
| Marino, K | 1 |
| Parlee, A | 1 |
| Orlando, R | 1 |
| Lerner, L | 1 |
| Strymish, J | 1 |
| Gupta, K | 1 |
| Weiss, S | 1 |
| Altboum, Z | 1 |
| Glinert, I | 1 |
| Schlomovitz, J | 1 |
| Sittner, A | 1 |
| Bar-David, E | 1 |
| Kobiler, D | 1 |
| Levy, H | 1 |
| Cazaubon, Y | 1 |
| Bourguignon, L | 1 |
| Goutelle, S | 1 |
| Martin, O | 2 |
| Maire, P | 1 |
| Ducher, M | 1 |
| Post, A | 1 |
| Ngbonda, D | 1 |
| Muyembe, JJ | 1 |
| Bertrand, S | 2 |
| Ceyssens, PJ | 1 |
| Mattheus, W | 1 |
| Verhaegen, J | 1 |
| Kuijpers, L | 1 |
| Van Geet, C | 1 |
| Babics, A | 1 |
| Roussellier, P | 1 |
| Weems, MF | 1 |
| Dereddy, NR | 1 |
| Arnold, SR | 1 |
| Cheng, MW | 1 |
| Lee, CM | 1 |
| Wang, NY | 1 |
| Wu, AY | 1 |
| Lin, CC | 1 |
| Weng, LC | 1 |
| Liu, CP | 1 |
| Shih, SC | 1 |
| Le Bourgeois, F | 1 |
| Germanaud, D | 1 |
| Bendavid, M | 1 |
| Bonnefoy, R | 1 |
| Desnous, B | 1 |
| Beyler, C | 1 |
| Blauwblomme, T | 1 |
| Elmaleh, M | 1 |
| Pierron, C | 1 |
| Lorrot, M | 1 |
| Bonacorsi, S | 1 |
| Basmaci, R | 1 |
| Mendoza-Olazarán, S | 1 |
| Morfín-Otero, R | 1 |
| Villarreal-Treviño, L | 1 |
| Rodríguez-Noriega, E | 1 |
| Llaca-Díaz, J | 1 |
| Camacho-Ortiz, A | 1 |
| González, GM | 1 |
| Casillas-Vega, N | 1 |
| Garza-González, E | 1 |
| Eibach, D | 1 |
| Al-Emran, HM | 1 |
| Dekker, DM | 1 |
| Krumkamp, R | 1 |
| Adu-Sarkodie, Y | 1 |
| Cruz Espinoza, LM | 1 |
| Ehmen, C | 1 |
| Boahen, K | 1 |
| Heisig, P | 1 |
| Im, J | 1 |
| Jaeger, A | 1 |
| von Kalckreuth, V | 1 |
| Pak, GD | 1 |
| Panzner, U | 1 |
| Park, SE | 1 |
| Reinhardt, A | 1 |
| Sarpong, N | 1 |
| Schütt-Gerowitt, H | 1 |
| Wierzba, TF | 1 |
| Marks, F | 1 |
| May, J | 1 |
| Tekeli, A | 1 |
| Ocal, DN | 1 |
| Ozmen, BB | 1 |
| Karahan, ZC | 1 |
| Dolapci, I | 1 |
| Rajchgot, J | 1 |
| Glicksman, R | 1 |
| Bogoch, II | 1 |
| Hallböök, H | 1 |
| Lidström, AK | 1 |
| Pauksens, K | 1 |
| Zambon, LS | 1 |
| Marta, GN | 1 |
| Chehter, N | 1 |
| Del Nero, LG | 1 |
| Cavallaro, MC | 1 |
| Aracil-García, B | 1 |
| Oteo-Iglesias, J | 1 |
| Cuevas-Lobato, Ó | 1 |
| Lara-Fuella, N | 1 |
| Pérez-Grajera, I | 1 |
| Fernández-Romero, S | 1 |
| Pérez-Vázquez, M | 1 |
| Campos, J | 1 |
| Valderrama, SL | 1 |
| González, PF | 1 |
| Caro, MA | 1 |
| Ardila, N | 1 |
| Ariza, B | 1 |
| Gil, F | 1 |
| Álvarez, C | 1 |
| McCollister, B | 1 |
| Kotter, CV | 1 |
| Frank, DN | 1 |
| Washburn, T | 1 |
| Jobling, MG | 1 |
| Choeyprasert, W | 1 |
| Hongeng, S | 1 |
| Anurathapan, U | 1 |
| Pakakasama, S | 1 |
| Abera, B | 1 |
| Kibret, M | 1 |
| Mulu, W | 1 |
| Kuretski, J | 1 |
| Dahya, V | 1 |
| Cason, L | 1 |
| Chalasani, P | 1 |
| Ramgopal, M | 1 |
| Misra, R | 1 |
| Prasad, KN | 1 |
| Margaritis, A | 1 |
| Galani, I | 1 |
| Chatzikonstantinou, M | 1 |
| Souli, M | 1 |
| Stupar, P | 1 |
| Opota, O | 1 |
| Longo, G | 1 |
| Prod'hom, G | 1 |
| Dietler, G | 1 |
| Greub, G | 1 |
| Kasas, S | 1 |
| Paulsson, M | 1 |
| Granrot, A | 1 |
| Ahl, J | 1 |
| Tham, J | 1 |
| Resman, F | 1 |
| Riesbeck, K | 1 |
| Månsson, F | 1 |
| Müderris, T | 1 |
| Ürkmez, FY | 1 |
| Küçüker, ŞA | 1 |
| Sağlam, MF | 1 |
| Yılmaz, GR | 1 |
| Güner, R | 1 |
| Güleşen, R | 1 |
| Açıkgöz, ZC | 1 |
| Al Omar, S | 1 |
| Anabtawi, N | 1 |
| Al Qasem, W | 1 |
| Rihani, R | 1 |
| Rocha, IV | 1 |
| Andrade, CADN | 1 |
| Campos, TL | 1 |
| Rezende, AM | 1 |
| Leal, NC | 1 |
| Vidal, CFL | 1 |
| Xavier, DE | 1 |
| Dohmae, S | 1 |
| Okubo, T | 1 |
| Higuchi, W | 1 |
| Takano, T | 1 |
| Isobe, H | 1 |
| Baranovich, T | 1 |
| Kobayashi, S | 1 |
| Uchiyama, M | 1 |
| Tanabe, Y | 1 |
| Itoh, M | 1 |
| Yamamoto, T | 1 |
| Liebowitz, LD | 1 |
| Blunt, MC | 1 |
| Rijavec, M | 1 |
| Müller-Premru, M | 1 |
| Zakotnik, B | 1 |
| Žgur-Bertok, D | 1 |
| Moniri, R | 1 |
| Dastehgoli, K | 1 |
| Dambrauskiene, A | 1 |
| Adukauskiene, D | 1 |
| Jeroch, J | 1 |
| Vitkauskiene, A | 1 |
| Aubert, T | 1 |
| Rovery, C | 1 |
| Bourhaba, K | 1 |
| Singeorzan, S | 1 |
| Heim, M | 1 |
| Crétel, E | 1 |
| Allison, MC | 1 |
| Sandoe, JA | 1 |
| Tighe, R | 1 |
| Simpson, IA | 1 |
| Hall, RJ | 1 |
| Elliott, TS | 1 |
| López-Dupla, M | 1 |
| Martínez, JA | 1 |
| Vidal, F | 1 |
| Almela, M | 1 |
| Soriano, A | 1 |
| Marco, F | 1 |
| López, J | 1 |
| Olona, M | 1 |
| Mensa, J | 1 |
| Migone, TS | 1 |
| Subramanian, GM | 1 |
| Zhong, J | 1 |
| Healey, LM | 1 |
| Corey, A | 1 |
| Devalaraja, M | 1 |
| Lo, L | 1 |
| Ullrich, S | 1 |
| Zimmerman, J | 1 |
| Chen, A | 1 |
| Lewis, M | 1 |
| Meister, G | 1 |
| Gillum, K | 1 |
| Sanford, D | 1 |
| Mott, J | 1 |
| Bolmer, SD | 1 |
| Srinivasan, A | 1 |
| Seifried, S | 1 |
| Zhu, L | 1 |
| Srivastava, DK | 1 |
| Shenep, JL | 1 |
| Bankowski, MJ | 1 |
| Vaudaux, P | 1 |
| Huggler, E | 1 |
| Arhin, FF | 1 |
| Moeck, G | 1 |
| Renzoni, A | 1 |
| Lew, DP | 1 |
| Dabanch P, J | 1 |
| Herrero C, D | 1 |
| Pavéz A, C | 1 |
| Veas P, N | 1 |
| Braun J, S | 1 |
| Porte T, L | 1 |
| Kanjanawongdeengam, P | 1 |
| Viseshsindh, W | 1 |
| Santanirand, P | 1 |
| Prathombutr, P | 1 |
| Nilkulwattana, S | 1 |
| Bossaer, JB | 1 |
| Hall, PD | 1 |
| Garrett-Mayer, E | 1 |
| Lemaire, X | 1 |
| Dehecq, C | 1 |
| Cattoen, C | 1 |
| Garnier, LD | 1 |
| Bournet, BS | 1 |
| Yazdanpanah, Y | 1 |
| Senneville, E | 1 |
| Franco, AI | 1 |
| Ortiz, J | 1 |
| Cabello, N | 1 |
| Ruiz Giardin, JM | 1 |
| Ruiz, JM | 1 |
| García, MI | 1 |
| Scheepers, MA | 1 |
| Keel, S | 1 |
| Michaelides, M | 1 |
| Lai, CC | 1 |
| Tan, CK | 1 |
| Chou, CH | 1 |
| Hsu, HL | 1 |
| Huang, YT | 1 |
| Liao, CH | 2 |
| Nakano, Y | 1 |
| Maybauer, MO | 1 |
| Maybauer, DM | 1 |
| Enkhbaatar, P | 1 |
| Traber, DL | 1 |
| Nicoletti, J | 1 |
| Kuster, SP | 1 |
| Sulser, T | 1 |
| Zbinden, R | 1 |
| Ruef, C | 1 |
| Ledergerber, B | 1 |
| Weber, R | 1 |
| Saengsuwan, P | 1 |
| Jaruratanasirikul, S | 1 |
| Jullangkoon, M | 1 |
| Aeinlang, N | 1 |
| Mazumder, SA | 1 |
| Cleveland, KO | 1 |
| Gaborieau, V | 1 |
| Weill, FX | 1 |
| Marchou, B | 1 |
| Mohanty, S | 1 |
| Gaind, R | 1 |
| Paglietti, B | 1 |
| Paul, P | 1 |
| Rubino, S | 1 |
| Deb, M | 1 |
| Kennedy, K | 2 |
| Collignon, P | 1 |
| Lin, PY | 1 |
| Chen, HL | 1 |
| Huang, CT | 1 |
| Chiu, CH | 1 |
| Lee, SS | 1 |
| Kim, Y | 1 |
| Redondo, MC | 1 |
| Gómez, M | 1 |
| Landaeta, ME | 1 |
| Ríos, H | 1 |
| Khalil, R | 1 |
| Guevara, RN | 1 |
| Palavecino, S | 1 |
| Figuera, M | 1 |
| Caldera, J | 1 |
| Rivera, R | 1 |
| Calvo, A | 1 |
| Vitelli, J | 1 |
| Morón, M | 1 |
| Nuñez, MJ | 1 |
| Sohn, KM | 1 |
| Yang, CH | 1 |
| Tsui, TL | 1 |
| Tsao, SM | 1 |
| Liu, KS | 1 |
| Chen, TY | 1 |
| Wang, YL | 1 |
| Teng, YH | 1 |
| Lee, YT | 2 |
| Fajardo Olivares, M | 1 |
| Hidalgo Orozco, R | 1 |
| Rodríguez Garrido, S | 1 |
| Rodríguez-Vidigal, FF | 1 |
| Vera Tomé, A | 1 |
| Robles Marcos, M | 1 |
| Menezes, GA | 1 |
| Harish, BN | 1 |
| Khan, MA | 1 |
| Goessens, WH | 1 |
| Hays, JP | 1 |
| Kaasch, AJ | 1 |
| Dinter, J | 1 |
| Goeser, T | 1 |
| Plum, G | 1 |
| Seifert, H | 1 |
| Spooner, AM | 1 |
| Deegan, C | 1 |
| D'Arcy, DM | 1 |
| Gowing, CM | 1 |
| Donnelly, MB | 1 |
| Corrigan, OI | 1 |
| Sideri, G | 1 |
| Kafetzis, DA | 1 |
| Vouloumanou, EK | 1 |
| Papadatos, JH | 1 |
| Papadimitriou, M | 1 |
| Falagas, ME | 1 |
| Thuo, N | 1 |
| Ungphakorn, W | 1 |
| Karisa, J | 1 |
| Muchohi, S | 1 |
| Muturi, A | 1 |
| Kokwaro, G | 1 |
| Thomson, AH | 1 |
| Maitland, K | 1 |
| Lieberman, TD | 1 |
| Michel, JB | 1 |
| Aingaran, M | 1 |
| Potter-Bynoe, G | 1 |
| Roux, D | 1 |
| Davis, MR | 1 |
| Skurnik, D | 1 |
| Leiby, N | 1 |
| LiPuma, JJ | 1 |
| Goldberg, JB | 1 |
| McAdam, AJ | 1 |
| Priebe, GP | 1 |
| Kishony, R | 1 |
| Batres Iglesias, AP | 1 |
| Pérez Cabeza, MI | 1 |
| Del Río Pardo, MJ | 1 |
| Castaño, M | 1 |
| Cranendonk, DR | 1 |
| van der Valk, M | 1 |
| Langenberg, ML | 1 |
| van der Meer, JT | 1 |
| Olut, AI | 1 |
| Avcı, M | 1 |
| Ozgenç, O | 1 |
| Altay, T | 1 |
| Coşkuner, SA | 1 |
| Ozsu Caymaz, S | 1 |
| Havuk, A | 1 |
| Tang, HJ | 1 |
| Chen, CC | 1 |
| Ko, WC | 5 |
| Grynik, A | 1 |
| Shaukat, S | 1 |
| Htut, EEP | 1 |
| Karas, JA | 2 |
| Alcalde-Vargas, A | 1 |
| Trigo-Salado, C | 1 |
| Leo Carnerero, E | 1 |
| De-la-Cruz-Ramírez, D | 1 |
| Herrera-Justiniano, JM | 1 |
| Nam, YS | 1 |
| Yang, HY | 1 |
| Park, KS | 1 |
| Jang, JH | 1 |
| Kim, YT | 1 |
| Jeong, JW | 1 |
| Suh, JT | 1 |
| Lee, HJ | 1 |
| Vlieghe, ER | 1 |
| Phe, T | 1 |
| De Smet, B | 1 |
| Veng, CH | 1 |
| Kham, C | 1 |
| Vanhoof, R | 1 |
| Lynen, L | 1 |
| Peetermans, WE | 1 |
| Jacobs, JA | 1 |
| Chong, Y | 1 |
| Shimoda, S | 1 |
| Yakushiji, H | 1 |
| Ito, Y | 1 |
| Miyamoto, T | 1 |
| Kamimura, T | 1 |
| Shimono, N | 1 |
| Akashi, K | 1 |
| Schelenz, S | 1 |
| Nwaka, D | 1 |
| Hunter, PR | 1 |
| Orr, D | 1 |
| Hedderwick, S | 1 |
| Rosenthal, EJ | 1 |
| Van Zonneveld, M | 1 |
| Droogh, JM | 1 |
| Fieren, MW | 1 |
| Gyssens, IC | 1 |
| Van Gelder, T | 1 |
| Weimar, W | 1 |
| Gomez, L | 1 |
| Garau, J | 3 |
| Estrada, C | 1 |
| Marquez, M | 1 |
| Dalmau, D | 1 |
| Xercavins, M | 2 |
| Martí, JM | 1 |
| Estany, C | 1 |
| Javaloyas, M | 1 |
| García-Somoza, D | 1 |
| Gudiol, F | 1 |
| Gasem, MH | 1 |
| Keuter, M | 1 |
| Dolmans, WM | 1 |
| Van Der Ven-Jongekrijg, J | 1 |
| Djokomoeljanto, R | 1 |
| Van Der Meer, JW | 1 |
| Woodford, N | 1 |
| Reynolds, R | 2 |
| Turton, J | 1 |
| Scott, F | 1 |
| Sinclair, A | 1 |
| Williams, A | 1 |
| Livermore, D | 1 |
| Marzano, AV | 1 |
| Mercogliano, M | 1 |
| Borghi, A | 1 |
| Facchetti, M | 1 |
| Caputo, R | 1 |
| Illinger, J | 1 |
| Mohammedi, I | 1 |
| Argaud, L | 1 |
| St Denis, M | 1 |
| Robert, D | 1 |
| Stephen, JM | 1 |
| Toleman, MA | 1 |
| Walsh, TR | 1 |
| Jones, RN | 2 |
| Livermore, DM | 2 |
| Nichols, T | 2 |
| Lamagni, TL | 1 |
| Potz, N | 1 |
| Duckworth, G | 1 |
| Mitchell, AE | 1 |
| Derrington, P | 1 |
| Hunt, LP | 1 |
| Oakhill, A | 1 |
| Marks, DI | 1 |
| Endimiani, A | 1 |
| Luzzaro, F | 1 |
| Perilli, M | 1 |
| Lombardi, G | 1 |
| Colì, A | 1 |
| Tamborini, A | 1 |
| Amicosante, G | 1 |
| Toniolo, A | 1 |
| Zanelli, G | 1 |
| Sansoni, S | 1 |
| Migliorini, L | 1 |
| Donati, E | 1 |
| Cellesi, C | 1 |
| Prabhu, RM | 1 |
| Elliott, MA | 1 |
| Patel, R | 1 |
| Drossou-Agakidou, V | 1 |
| Roilides, E | 1 |
| Papakyriakidou-Koliouska, P | 1 |
| Agakidis, C | 1 |
| Nikolaides, N | 1 |
| Sarafidis, K | 1 |
| Kremenopoulos, G | 1 |
| Hardman, SC | 1 |
| Carr, SJ | 1 |
| Swann, RA | 1 |
| Aoki, S | 1 |
| Hirakata, Y | 1 |
| Kondoh, A | 1 |
| Gotoh, N | 1 |
| Yanagihara, K | 1 |
| Miyazaki, Y | 1 |
| Tomono, K | 1 |
| Yamada, Y | 1 |
| Kohno, S | 1 |
| Kamihira, S | 1 |
| Kim, DM | 1 |
| Park, WB | 3 |
| Lee, KD | 3 |
| Kim, HB | 4 |
| Oh, MD | 4 |
| Kim, EC | 4 |
| Choe, KW | 4 |
| Arnold, DM | 1 |
| Smaill, F | 1 |
| Warkentin, TE | 1 |
| Christjanson, L | 1 |
| Walker, I | 1 |
| Slinger, R | 1 |
| Desjardins, M | 1 |
| McCarthy, AE | 1 |
| Ramotar, K | 1 |
| Jessamine, P | 1 |
| Guibord, C | 1 |
| Toye, B | 1 |
| Yousef, AA | 1 |
| Fryer, CJ | 1 |
| Chedid, FD | 1 |
| Abbas, AA | 1 |
| Felimban, SK | 1 |
| Khattab, TM | 1 |
| Viganò, EF | 1 |
| Vasconi, E | 1 |
| Agrappi, C | 1 |
| Clerici, P | 1 |
| Melloni, P | 1 |
| Monno, R | 1 |
| Rendina, M | 1 |
| Ceci, G | 1 |
| Rizzo, C | 1 |
| Luzzi, I | 1 |
| Francavilla, A | 1 |
| Rizzo, G | 1 |
| Ierardi, E | 1 |
| Baker, SD | 1 |
| Horger, DC | 1 |
| Keane, TE | 1 |
| Drinković, D | 1 |
| Taylor, SL | 1 |
| Lang, S | 1 |
| Otağ, F | 1 |
| Ersöz, G | 1 |
| Salcioğlu, M | 1 |
| Bal, C | 1 |
| Schneider, I | 1 |
| Bauernfeind, A | 1 |
| Yan, JJ | 1 |
| Yu, WL | 1 |
| Lee, HC | 2 |
| Wang, LR | 1 |
| Chuang, YC | 1 |
| Zimmermann, O | 1 |
| de Ciman, R | 1 |
| Gross, U | 1 |
| Hsu, RB | 1 |
| Chen, RJ | 1 |
| Lin, FY | 1 |
| Chu, SH | 1 |
| Benenson, S | 1 |
| Yinnon, AM | 1 |
| Schlesinger, Y | 1 |
| Rudensky, B | 1 |
| Raveh, D | 1 |
| Kizirgil, A | 1 |
| Demirdag, K | 1 |
| Ozden, M | 1 |
| Bulut, Y | 1 |
| Yakupogullari, Y | 1 |
| Toraman, ZA | 1 |
| Castagnola, E | 1 |
| Haupt, R | 1 |
| Micozzi, A | 1 |
| Caviglia, I | 1 |
| Testi, AM | 1 |
| Giona, F | 1 |
| Parodi, S | 1 |
| Girmenia, C | 1 |
| Rókusz, L | 1 |
| László, L | 1 |
| Guo, SM | 1 |
| Grigull, L | 1 |
| Linderkamp, C | 1 |
| Sander, A | 1 |
| Schmid, H | 1 |
| Mutschler, U | 1 |
| Welte, K | 1 |
| Beilken, A | 1 |
| Cirioni, O | 1 |
| Giacometti, A | 1 |
| Ghiselli, R | 1 |
| Dell'Acqua, G | 1 |
| Orlando, F | 1 |
| Mocchegiani, F | 1 |
| Silvestri, C | 1 |
| Licci, A | 1 |
| Saba, V | 1 |
| Scalise, G | 1 |
| Balaban, N | 1 |
| Citak, EC | 1 |
| Oguz, A | 1 |
| Karadeniz, C | 1 |
| Okur, V | 1 |
| Basustaoglu, A | 1 |
| Arman, D | 1 |
| Tappe, D | 1 |
| Claus, H | 1 |
| Kern, J | 1 |
| Marzinzig, A | 1 |
| Frosch, M | 1 |
| Abele-Horn, M | 1 |
| Roberts, MTM | 1 |
| Enoch, DA | 1 |
| Harris, KA | 1 |
| Wang, JY | 1 |
| Hwang, JJ | 1 |
| Hsu, CN | 1 |
| Lin, LC | 1 |
| Fernandez-Hidalgo, N | 1 |
| Almirante, B | 1 |
| Calleja, R | 1 |
| Ruiz, I | 1 |
| Planes, AM | 2 |
| Rodriguez, D | 1 |
| Pigrau, C | 1 |
| Pahissa, A | 2 |
| Beno, P | 1 |
| Krcmery, V | 1 |
| Demitrovicova, A | 1 |
| Wang, CY | 1 |
| Chuang, YM | 1 |
| Teng, LJ | 1 |
| Lee, LN | 1 |
| Yang, PC | 1 |
| Kuo, SH | 1 |
| Fortún, J | 1 |
| Grill, F | 1 |
| Martín-Dávila, P | 1 |
| Blázquez, J | 1 |
| Tato, M | 1 |
| Sánchez-Corral, J | 1 |
| García-San Miguel, L | 1 |
| Moreno, S | 1 |
| Yilmaz, G | 1 |
| Aydin, K | 1 |
| Koksal, I | 1 |
| Caylan, R | 1 |
| Akcay, K | 1 |
| Arslan, M | 1 |
| Bang, JW | 1 |
| Kim, NJ | 1 |
| Chang, CM | 1 |
| Huang, GC | 1 |
| Lee, IW | 1 |
| Huang, SS | 1 |
| Leu, HS | 1 |
| Dimitrov, T | 1 |
| Udo, EE | 1 |
| Albaksami, O | 1 |
| Kilani, AA | 1 |
| Shehab, EMR | 1 |
| Papp, M | 1 |
| Farkas, A | 1 |
| Udvardy, M | 1 |
| Tornai, I | 1 |
| Kulwichit, W | 1 |
| Chatsuwan, T | 1 |
| Unhasuta, C | 1 |
| Pulsrikarn, C | 1 |
| Bangtrakulnonth, A | 1 |
| Chongthaleong, A | 1 |
| Kilani, B | 1 |
| Ammari, L | 1 |
| Benaïssa, HT | 1 |
| Ben Chaabane, T | 1 |
| Fendri, C | 1 |
| Hung, PH | 1 |
| Chiu, YL | 1 |
| Vandijck, DM | 1 |
| Decruyenaere, JM | 1 |
| Depuydt, PO | 1 |
| Blot, SI | 1 |
| Otter, JA | 1 |
| Klein, JL | 1 |
| Watts, TL | 1 |
| Kearns, AM | 1 |
| French, GL | 1 |
| Elwood, ET | 1 |
| Sommerville, DN | 1 |
| Murray, JD | 1 |
| Negroni, R | 1 |
| Arechavala, AI | 1 |
| Maiolo, E | 1 |
| Santiso, G | 1 |
| Bianchi, MH | 1 |
| González, G | 1 |
| Orduna, T | 1 |
| Rodríguez-Baño, J | 1 |
| Martí, S | 1 |
| Soto, S | 1 |
| Fernández-Cuenca, F | 1 |
| Cisneros, JM | 1 |
| Pachón, J | 1 |
| Pascual, A | 1 |
| Martínez-Martínez, L | 1 |
| McQueary, C | 1 |
| Actis, LA | 1 |
| Vila, J | 1 |
| Tulsidas, H | 1 |
| Ong, YY | 1 |
| Chan, KC | 1 |
| Kotilainen, P | 1 |
| Huovinen, P | 1 |
| Eerola, E | 1 |
| Burnett, RJ | 1 |
| Haverstock, DC | 1 |
| Dellinger, EP | 1 |
| Reinhart, HH | 1 |
| Bohnen, JM | 1 |
| Rotstein, OD | 1 |
| Vogel, SB | 1 |
| Solomkin, JS | 1 |
| MacKay, AD | 1 |
| Mehta, A | 1 |
| Trauner, M | 1 |
| Grasmug, E | 1 |
| Stauber, RE | 1 |
| Hammer, HF | 1 |
| Hoefler, G | 1 |
| Reisinger, EC | 1 |
| Amyes, SG | 1 |
| Baird, DR | 1 |
| Crook, DW | 1 |
| Gillespie, SH | 1 |
| Howard, AJ | 1 |
| Oppenhiem, BA | 1 |
| Pedler, SJ | 1 |
| Paull, A | 1 |
| Tompkins, DS | 1 |
| Lawrie, SA | 1 |
| Peña, C | 1 |
| Albareda, JM | 1 |
| Pallares, R | 1 |
| Pujol, M | 1 |
| Tubau, F | 1 |
| Ariza, J | 1 |
| Burman, WJ | 1 |
| Cohn, DL | 1 |
| Reves, RR | 1 |
| Wilson, ML | 1 |
| Gopinath, R | 1 |
| Keystone, JS | 1 |
| Kain, KC | 1 |
| Imrie, KR | 1 |
| Prince, HM | 1 |
| Couture, F | 1 |
| Brandwein, JM | 1 |
| Keating, A | 1 |
| Nielsen, PE | 1 |
| Thelle, T | 1 |
| Tvede, M | 1 |
| Simon, CH | 1 |
| Markusse, HM | 1 |
| Chan, TY | 1 |
| Chow, DP | 1 |
| Ng, KC | 1 |
| Pang, KW | 1 |
| McBride, GA | 1 |
| Stals, FS | 1 |
| vd Bogaard, AE | 1 |
| Bruggeman, CA | 1 |
| Belliveau, PP | 1 |
| Nightingale, CH | 2 |
| Qunitiliani, R | 1 |
| Maderazo, EG | 1 |
| Elcuaz, R | 1 |
| Lluch-Perales, JF | 1 |
| Gómez, E | 1 |
| Suárez, J | 1 |
| Hernández, M | 1 |
| LaFarga, B | 1 |
| D'Antonio, D | 2 |
| Piccolomini, R | 1 |
| Iacone, A | 2 |
| Fioritoni, G | 2 |
| Parruti, G | 1 |
| Betti, S | 2 |
| Quaglietta, AM | 1 |
| Accorsi, P | 1 |
| Dell'Isola, M | 2 |
| Favalli, C | 1 |
| Court, EA | 1 |
| Watson, AD | 1 |
| Martin, P | 1 |
| Ohl, CA | 1 |
| Sullivan, N | 1 |
| Paparello, S | 1 |
| Hagensee, ME | 1 |
| Benyunes, M | 1 |
| Miller, JA | 1 |
| Spach, DH | 2 |
| Cogollos, R | 1 |
| Alós, JI | 2 |
| Gómez-Garcés, JL | 1 |
| McDonald, GR | 1 |
| de Jong, P | 1 |
| de Jong, M | 1 |
| Kuijper, E | 1 |
| van der Lelie, J | 1 |
| Bijl, W | 1 |
| Janknegt, RA | 1 |
| Lobo, IM | 1 |
| Silva, NF | 1 |
| Assef, MC | 1 |
| Mangini, C | 1 |
| Silva, ML | 1 |
| Bortoletto, ML | 1 |
| Mendonça, JS | 1 |
| Levi, GC | 1 |
| Capdevila, JA | 1 |
| Segarra, A | 1 |
| Ramírez-Arellano, M | 1 |
| Piera, L | 1 |
| Martínez-Vázquez, JM | 1 |
| Sheth, KJ | 1 |
| Henrickson, KJ | 2 |
| Romulo, RL | 1 |
| Palardy, JE | 2 |
| Opal, SM | 2 |
| Kemmerly, SA | 1 |
| Pankey, GA | 1 |
| Peterson, MC | 1 |
| Farr, RW | 1 |
| Castiglia, M | 1 |
| Ena, J | 1 |
| Houston, A | 1 |
| Wenzel, RP | 1 |
| Rubenstein, EB | 1 |
| Rolston, K | 1 |
| Benjamin, RS | 1 |
| Loewy, J | 1 |
| Escalante, C | 1 |
| Manzullo, E | 1 |
| Hughes, P | 1 |
| Moreland, B | 1 |
| Fender, A | 1 |
| Funke, G | 1 |
| Rosner, H | 1 |
| Wu, JJ | 1 |
| Hsiue, TR | 1 |
| Hsieh, WC | 2 |
| Nitsche, D | 1 |
| Schulze, C | 1 |
| Oesser, S | 1 |
| Dalhoff, A | 1 |
| Sack, M | 1 |
| Gimeno, C | 1 |
| Navarro, D | 1 |
| Savall, F | 1 |
| Millás, E | 1 |
| Farga, MA | 1 |
| Cisterna, R | 1 |
| García-de-Lomas, J | 1 |
| Shafran, SD | 2 |
| Singer, J | 2 |
| Zarowny, DP | 1 |
| Phillips, P | 1 |
| Salit, I | 2 |
| Walmsley, SL | 1 |
| Fong, IW | 1 |
| Gill, MJ | 1 |
| Rachlis, AR | 1 |
| Lalonde, RG | 1 |
| Fanning, MM | 1 |
| Tsoukas, CM | 2 |
| Vijayvargiya, R | 1 |
| Veis, JH | 1 |
| Amodio-Groton, M | 1 |
| Madu, A | 1 |
| Madu, CN | 1 |
| Briceland, LL | 1 |
| Seligman, M | 1 |
| McMaster, P | 1 |
| Miller, MH | 1 |
| Sakamoto, M | 1 |
| Saruta, K | 1 |
| Nakazawa, Y | 1 |
| Shindo, N | 1 |
| Maezawa, H | 1 |
| Yoshikawa, K | 1 |
| Yoshida, M | 1 |
| Shiba, K | 1 |
| Sakai, O | 1 |
| Saito, A | 1 |
| Meisenberg, B | 1 |
| Gollard, R | 1 |
| Brehm, T | 1 |
| McMillan, R | 1 |
| Miller, W | 1 |
| Wang, JH | 2 |
| Liu, YC | 1 |
| Yen, MY | 1 |
| Chen, YS | 1 |
| Wann, SR | 1 |
| Cheng, DL | 1 |
| Garcia, R | 1 |
| Raad, I | 1 |
| Pieroni, P | 1 |
| Goodfellow, J | 1 |
| Reesor, L | 1 |
| Louie, M | 1 |
| Simor, AE | 1 |
| Mani, V | 1 |
| Cartwright, K | 1 |
| Dooley, J | 1 |
| Swarbrick, E | 1 |
| Fairclough, P | 1 |
| Oakley, C | 1 |
| Berman, AJ | 1 |
| Del Priore, LV | 1 |
| Fischer, CK | 1 |
| Yagel, SK | 1 |
| Barrett, JF | 1 |
| Amaratunga, DJ | 1 |
| Frosco, MB | 1 |
| Jones, EM | 1 |
| McMullin, CM | 1 |
| Hedges, AJ | 1 |
| Lovering, AM | 1 |
| White, LO | 1 |
| Reeves, DS | 1 |
| MacGowan, AP | 1 |
| Kollef, MH | 1 |
| Vlasnik, J | 1 |
| Sharpless, L | 1 |
| Pasque, C | 1 |
| Murphy, D | 1 |
| Fraser, V | 1 |
| Tee, W | 1 |
| Mijch, A | 1 |
| Hung, CC | 2 |
| Chen, YC | 1 |
| Fang, CT | 1 |
| Chang, SC | 1 |
| Luh, KT | 1 |
| Mascellino, MT | 1 |
| Farinelli, S | 1 |
| Iegri, F | 1 |
| Iona, E | 1 |
| Gabay, B | 1 |
| Samra, Z | 1 |
| Hodak, E | 1 |
| Pitlik, S | 1 |
| Threlfall, EJ | 1 |
| Cheasty, T | 1 |
| Graham, A | 1 |
| Rowe, B | 1 |
| Jönsson, I | 1 |
| Monsen, T | 1 |
| Wiström, J | 1 |
| Rosenberg, R | 1 |
| Barzilai, A | 1 |
| Rubinovich, B | 1 |
| Blank-Porat, D | 1 |
| Rubinstein, E | 1 |
| Keller, N | 1 |
| Levi, I | 1 |
| Jhung, JW | 1 |
| Keith, JC | 1 |
| Parejo, NA | 1 |
| Young, LD | 1 |
| Bhattacharjee, A | 1 |
| Parenti, DM | 1 |
| Williams, PL | 1 |
| Hafner, R | 1 |
| Jacobs, MR | 1 |
| Hojczyk, P | 1 |
| Hooton, TM | 1 |
| Barber, TW | 1 |
| Simpson, G | 1 |
| van der Horst, C | 1 |
| Currier, J | 1 |
| Powderly, WG | 1 |
| Limjoco, M | 1 |
| Ellner, JJ | 1 |
| Kerr, KG | 1 |
| Armitage, HT | 1 |
| McWhinney, PH | 1 |
| Dubé, MP | 1 |
| Torriani, FJ | 1 |
| See, D | 1 |
| Havlir, DV | 1 |
| Kemper, CA | 2 |
| Leedom, JM | 2 |
| Tilles, JG | 2 |
| McCutchan, JA | 2 |
| Sattler, FR | 1 |
| Krumpe, PE | 1 |
| Cohn, S | 1 |
| Garreltes, J | 1 |
| Ramirez, J | 1 |
| Coulter, H | 1 |
| Haverstock, D | 1 |
| Echols, R | 1 |
| Casado, JL | 1 |
| Valdezate, S | 1 |
| Calderon, C | 1 |
| Navas, E | 1 |
| Frutos, B | 1 |
| Guerrero, A | 1 |
| Martinez-Beltran, J | 1 |
| Borer, A | 1 |
| Gilad, J | 1 |
| Sikuler, E | 1 |
| Riesenberg, K | 1 |
| Schlaeffer, F | 1 |
| Buskila, D | 1 |
| Onyeji, CO | 1 |
| Bui, KQ | 1 |
| Owens, RC | 1 |
| Nicolau, DP | 1 |
| Quintiliani, R | 1 |
| Kern, WV | 1 |
| Cometta, A | 1 |
| De Bock, R | 1 |
| Langenaeken, J | 1 |
| Paesmans, M | 1 |
| Gaya, H | 1 |
| Perea, S | 1 |
| Hidalgo, M | 1 |
| Arcediano, A | 1 |
| Ramos, MJ | 1 |
| Gomez, C | 1 |
| Hornedo, J | 1 |
| Lumbreras, C | 1 |
| Folgueira, D | 1 |
| Cortes-Funes, H | 1 |
| Rodriguez-Noriega, A | 1 |
| Rodríguez-Carballeira, M | 1 |
| Gómez-Vera, JR | 1 |
| Coll, I | 1 |
| Vidal, D | 1 |
| Llovet, T | 1 |
| Ruíz-Bremón, A | 1 |
| Hardy, D | 1 |
| Amsterdam, D | 1 |
| Mandell, LA | 1 |
| Rotstein, C | 1 |
| Axtell, RA | 1 |
| Hoover, SM | 1 |
| Kuhn, SM | 1 |
| Pritchett, J | 1 |
| Kehl, SC | 1 |
| Klein, JP | 1 |
| Paterson, DL | 1 |
| Mulazimoglu, L | 1 |
| Casellas, JM | 1 |
| Goossens, H | 1 |
| Von Gottberg, A | 1 |
| Mohapatra, S | 1 |
| Trenholme, GM | 1 |
| Klugman, KP | 1 |
| McCormack, JG | 1 |
| Yu, VL | 1 |
| Thorne, A | 1 |
| Khorasheh, S | 1 |
| Raboud, JM | 1 |
| Wu, AW | 1 |
| Lemieux, C | 1 |
| Lasry, S | 1 |
| Simon, J | 1 |
| Marais, A | 1 |
| Pouchot, J | 1 |
| Vinceneux, P | 1 |
| Boussougant, Y | 1 |
| Baum, HV | 1 |
| Franz, U | 1 |
| Geiss, HK | 1 |
| Persson, L | 1 |
| Vikerfors, T | 1 |
| Sjöberg, L | 1 |
| Engervall, P | 1 |
| Tidefelt, U | 1 |
| Suankratay, C | 1 |
| Phantumchinda, K | 1 |
| Tachawiboonsak, W | 1 |
| Wilde, H | 1 |
| Hsieh, SM | 1 |
| Hsiao, CF | 1 |
| Chen, MY | 1 |
| Sheng, WH | 1 |
| Cheong, HJ | 1 |
| Yoo, CW | 1 |
| Sohn, JW | 1 |
| Kim, WJ | 1 |
| Kim, MJ | 1 |
| Park, SC | 1 |
| Zaidi, Y | 1 |
| Hastings, M | 1 |
| Murray, J | 1 |
| Hassan, R | 1 |
| Kurshid, M | 1 |
| Mahendra, P | 1 |
| Carretto, E | 1 |
| Barbarini, D | 1 |
| Marzani, FC | 1 |
| Fumagalli, P | 1 |
| Monzillo, V | 1 |
| Emmi, V | 1 |
| Rodríguez-Avial, I | 1 |
| Rodríguez-Avial, C | 1 |
| Picazo, JJ | 1 |
| James, D | 1 |
| Reacher, M | 1 |
| Graham, C | 1 |
| Stephens, P | 1 |
| Johnson, AP | 1 |
| George, RC | 1 |
| Wood, L | 1 |
| Dhawan, B | 1 |
| Khan, U | 1 |
| Das, BK | 1 |
| Mathur, P | 1 |
| Pandhi, RK | 1 |
| Kapil, A | 1 |
| de Lalla, F | 1 |
| Maserati, R | 1 |
| Scarpellini, P | 1 |
| Nicolin, R | 1 |
| Caccamo, F | 1 |
| Rigoli, R | 1 |
| Bauwens, JE | 1 |
| Schacker, TW | 1 |
| Mustafa, MM | 1 |
| Bowden, RA | 1 |
| Pizzigallo, E | 1 |
| Piergallini, A | 1 |
| Di Gianfilippo, R | 1 |
| Olioso, P | 1 |
| Torlontano, G | 1 |
| Kalager, T | 1 |
| Andersen, BM | 1 |
| Bergan, T | 1 |
| Brubakk, O | 1 |
| Bruun, JN | 1 |
| Døskeland, B | 1 |
| Hellum, KB | 1 |
| Hopen, G | 1 |
| von der Lippe, E | 1 |
| Rahm, V | 1 |
| Chew, SK | 1 |
| Monteiro, EH | 1 |
| Lim, YS | 1 |
| Allen, DM | 1 |
| Gür, D | 1 |
| Kocagöz, T | 1 |
| Akalin, HE | 1 |
| Decker, CF | 1 |
| Martin, GJ | 1 |
| Barham, WB | 1 |
| Paparello, SF | 1 |
| Meng, TC | 1 |
| Nussbaum, J | 1 |
| Chiu, J | 1 |
| Feigal, DF | 1 |
| Bartok, AE | 1 |
| Deresinski, SC | 1 |
| Rodríguez, C | 1 |
| Amor, E | 1 |
| Gómez Garcés, JL | 1 |
| Wimperis, JZ | 1 |
| Baglin, TP | 1 |
| Marcus, RE | 1 |
| Warren, RE | 1 |
| López, P | 1 |
| Salas, R | 1 |
| Vinuesa, T | 1 |
| Rosell, F | 1 |
| Roosendaal, R | 1 |
| Bakker-Woudenberg, IA | 1 |
| van den Berghe-van Raffe, M | 1 |
| Vink-van den Berg, JC | 1 |
| Michel, MF | 1 |
| Brook, I | 1 |
| Elliott, TB | 1 |
| Villanueva Marcos, JL | 1 |
| Villar Ráez, A | 1 |
| Kindelán Jaquotot, JM | 1 |
| Jurado Jiménez, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Artificial Intelligence-based Prescription Support Software iAST® for the Choice of Empirical and Semi-targeted Antibiotic Treatment[NCT06174519] | 325 participants (Actual) | Observational | 2023-08-01 | Completed | |||
| Risk-factors for Multidrug-resistant (MDR) and Extensively Drug-resistant (XDR) Bacteria Colonization Among Patients at High Risk of STIs[NCT03767374] | 2,186 participants (Actual) | Observational | 2018-05-11 | Active, not recruiting | |||
| Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia[NCT03023384] | 547 participants (Anticipated) | Observational [Patient Registry] | 2016-12-31 | Recruiting | |||
| A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects[NCT00639678] | Phase 3 | 322 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.[NCT00000641] | Phase 2 | 90 participants | Interventional | Completed | |||
| Short Daily Alcohol Locks for the Prevention of Tunneled Catheter Infection in Patients With Haematological Disease. Randomised Placebo Controlled Trial[NCT00122642] | Phase 2/Phase 3 | 440 participants (Anticipated) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants who developed an anti-raxibacumab antibody response during the study were assessed. .Immunogenicity testing was performed to determine if raxibacumab induced an anti-raxibacumab immune response. Testing comprised of 2 assays (screening and confirmatory). The screening assay (direct binding) was an electrochemiluminescence (ECL)-based bridging assay. A rabbit polyclonal antibody was used as a positive control. Samples above the assay cut point were considered positive. Samples identified as positive in the screening assay were confirmed positive in a confirmatory assay. Samples must have demonstrated a significant percent drop in the confirmatory inhibition of binding assay to be considered positive. The inhibition of binding confirmatory assay was performed identically to the direct binding screening assay with the exception that the samples were tested in parallel with excess unlabeled raxibacumab. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) |
|---|---|
| Placebo - Single-Dose | 0 |
| Placebo - Double-Dose | 0 |
| Raxibacumab - Single-Dose | 0 |
| Raxibacumab - Double-Dose | 0 |
Clinical thyroid parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) |
|---|---|
| Placebo - Single-Dose | 0 |
| Placebo - Double-Dose | 0 |
| Raxibacumab - Single-Dose | 0 |
| Raxibacumab - Double-Dose | 0 |
Blood was collected from each participant at selected times post dose, and serum specimens were analyzed for raxibacumab using a validated electrochemiluminescense-based assay. The individual serum raxibacumab concentration data were summarized by nominal collection time and treatment group using descriptive statistics. Blood samples for serum raxibacumab concentration measurement were collected from participants who received a single-dose prior to administration of the raxibacumab and diphenhydramine doses on Day 0, at 30 minutes and 2 to 6 hours after completion of the raxibacumab infusion, and at 14, 28, and 56 days after the raxibacumab dose. (NCT00639678)
Timeframe: Pre-dose on Day 0, at 30 minutes and 2 to 6 hours after completion of raxibacumab infusion, and at 14, 28, and 56 days after the raxibacumab dose
| Intervention | Micrograms per milliliter (μg/mL) (Mean) | |||||
|---|---|---|---|---|---|---|
| Predose | 30 minutes post-dose | 2-6 hours post-dose | Day 14 | Day 28 | Day 56 | |
| Raxibacumab - Single-Dose | 0.048 | 928.447 | 881.586 | 311.669 | 199.043 | 89.021 |
Blood was collected from each participant at selected times post dose, and serum specimens were analyzed for raxibacumab using a validated electrochemiluminescense-based assay. The individual serum raxibacumab concentration data were summarized by nominal collection time and treatment group using descriptive statistics. For the participants that received two doses, blood samples for serum raxibacumab concentration measurement were collected from participants prior to administration of the raxibacumab and diphenhydramine doses on Days 0 and 14, at 30 minutes and 2 to 6 hours after completion of each raxibacumab infusion, and at 28, 42, 56, and 70 days after the 1st raxibacumab dose. (NCT00639678)
Timeframe: Pre-dose on Days 0 and 14, at 30 minutes and 2 to 6 hours after completion of each raxibacumab infusion, and at 28, 42, 56, and 70 days after the 1st raxibacumab dose
| Intervention | Micrograms per milliliter (μg/mL) (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dose 1 - Predose | Dose 1 - 30 minutes post-dose | Dose 1 - 2-6 hours post-dose | Dose 2 - Predose | Dose 2 - 30 minutes post-dose | Dose 2 - 2-6 hours post-dose | Dose 2 - Day 14 | Dose 2 - Day 28 | Dose 2 - Day 42 | Dose 2 - Day 56 | |
| Raxibacumab - Double-Dose | 0 | 1012.564 | 973.910 | 314.374 | 1246.223 | 1211.572 | 543.767 | 334.431 | 213.463 | 137.878 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. This includes worsening (eg, increase in frequency or severity) of pre-existing conditions. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |
|---|---|---|
| Any AE | Any SAE | |
| Placebo - Double-Dose | 6 | 1 |
| Placebo - Single-Dose | 32 | 0 |
| Raxibacumab - Double-Dose | 10 | 1 |
| Raxibacumab - Single-Dose | 103 | 0 |
The number of participants with at least a 2-grade worsening from Baseline in electrolyte toxicities were assessed. Electrolyte function parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hypernatremia, any >=2-grade worsening | Hyponatremia, any >=2-grade worsening | Hyperkalemia, any >=2-grade worsening | Hypokalemia, any >=2-grade worsening | Hypomagnesemia, any >=2-grade worsening | HrC/adjusted for albumin, any >=2-grade worsening | HoC/adjusted for albumin, any >=2-grade worsening | Hypercalcemia/unadjusted, any >=2-grade worsening | Hypocalcemia/unadjusted, any >=2-grade worsening | Hypophosphatemia, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 5 |
The number of participants with at least a 2-grade worsening from Baseline in hematological toxicities were assessed. Clinical hematological parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Leukocytosis, any >=2-grade worsening | Leukopenia, any >=2-grade worsening | Neutropenia, any >=2-grade worsening | Lymphopenia, any >=2-grade worsening | Hemoglobin, any >=2-grade worsening | Platelet, any >=2-grade worsening | Prothrombin Time, any >=2-grade worsening | Activated PTT, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 2 | 1 | 2 | 1 | 0 | 0 | 2 | 0 |
The number of participants with at least a 2-grade worsening from Baseline in liver toxicities were assessed. Liver function parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| AST, any >=2-grade worsening | ALT, any >=2-grade worsening | GGT, any >=2-grade worsening | ALP, any >=2-grade worsening | Hyperbilirubinemia, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 0 | 1 | 0 | 0 | 0 |
The number of participants with at least a 2-grade worsening from Baseline in other chemistry toxicities were assessed. Other clinical chemistry parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Creatinine, any >=2-grade worsening | BUN, any >=2-grade worsening | Hypoalbuminemia, any >=2-grade worsening | Hyperuricemia, any >=2-grade worsening | Hyperglycemia, any >=2-grade worsening | Hypoglycemia, any >=2-grade worsening | Amylase, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| Raxibacumab - Single-Dose | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
Urinalysis parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |
|---|---|---|
| Proteinuria, any >=2-grade worsening | Hematuria, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 |
| Placebo - Single-Dose | 3 | 4 |
| Raxibacumab - Double-Dose | 0 | 2 |
| Raxibacumab - Single-Dose | 8 | 12 |
Electrolyte function parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypernatremia, Grade 1 | Hypernatremia, Grade 2 | Hypernatremia, Grade 3 | Hypernatremia, Grade 4 | Hyponatremia, Grade 1 | Hyponatremia, Grade 2 | Hyponatremia, Grade 3 | Hyponatremia, Grade 4 | Hyperkalemia, Grade 1 | Hyperkalemia, Grade 2 | Hyperkalemia, Grade 3 | Hyperkalemia, Grade 4 | Hypokalemia, Grade 1 | Hypokalemia, Grade 2 | Hypokalemia, Grade 3 | Hypokalemia, Grade 4 | Hypomagnesemia, Grade 1 | Hypomagnesemia, Grade 2 | Hypomagnesemia, Grade 3 | Hypomagnesemia, Grade 4 | Hypercalcemia (HrC)/ adjusted for albumin, Grade 1 | HrC/ adjusted for albumin, Grade 2 | HrC/ adjusted for albumin, Grade 3 | HrC/ adjusted for albumin, Grade 4 | Hypocalcemia (HoC)/ adjusted for albumin, Grade 1 | HoC adjusted for albumin, Grade 2 | HoC/ adjusted for albumin, Grade 3 | HoC/ adjusted for albumin, Grade 4 | Hypercalcemia/ unadjusted, Grade 1 | Hypercalcemia/ unadjusted, Grade 2 | Hypercalcemia/ unadjusted, Grade 3 | Hypercalcemia/ unadjusted, Grade 4 | Hypocalcemia/ unadjusted, Grade 1 | Hypocalcemia/ unadjusted, Grade 2 | Hypocalcemia/ unadjusted, Grade 3 | Hypocalcemia/ unadjusted, Grade 4 | Hypophosphatemia, Grade 1 | Hypophosphatemia, Grade 2 | Hypophosphatemia, Grade 3 | Hypophosphatemia, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 0 | 0 | 0 | 0 | 20 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 5 | 0 | 0 |
Clinical hematological parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukocytosis, Grade 1 | Leukocytosis, Grade 2 | Leukocytosis, Grade 3 | Leukocytosis, Grade 4 | Leukopenia, Grade 1 | Leukopenia, Grade 2 | Leukopenia, Grade 3 | Leukopenia, Grade 4 | Neutropenia, Grade 1 | Neutropenia, Grade 2 | Neutropenia, Grade 3 | Neutropenia, Grade 4 | Lymphopenia, Grade 1 | Lymphopenia, Grade 2 | Lymphopenia, Grade 3 | Lymphopenia, Grade 4 | Hemoglobin, Grade 1 | Hemoglobin, Grade 2 | Hemoglobin, Grade 3 | Hemoglobin, Grade 4 | Platelet, Grade 1 | Platelet, Grade 2 | Platelet, Grade 3 | Platelet, Grade 4 | Prothrombin Time, Grade 1 | Prothrombin Time, Grade 2 | Prothrombin Time, Grade 3 | Prothrombin Time, Grade 4 | Activated PartialThromboplastinTime(PTT) , Grade 1 | Activated PTT, Grade 2 | Activated PTT, Grade 3 | Activated PTT, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 4 | 1 | 1 | 0 | 9 | 1 | 0 | 0 | 4 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Raxibacumab - Double-Dose | 2 | 2 | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 15 | 2 | 1 | 0 | 25 | 6 | 0 | 0 | 8 | 1 | 0 | 1 | 3 | 1 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 10 | 0 | 0 | 0 |
Liver function parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspartate amino transferase (AST), Grade 1 | AST, Grade 2 | AST, Grade 3 | AST, Grade 4 | Alanine amino transferase(ALT), Grade 1 | ALT, Grade 2 | ALT, Grade 3 | ALT, Grade 4 | Gamma-glutamyl-transferase (GGT), Grade 1 | GGT, Grade 2 | GGT, Grade 3 | GGT, Grade 4 | Alkaline Phosphatase(ALP), Grade 1 | ALP, Grade 2 | ALP, Grade 3 | ALP, Grade 4 | Hyperbilirubinemia, Grade 1 | Hyperbilirubinemia, Grade 2 | Hyperbilirubinemia, Grade 3 | Hyperbilirubinemia, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 7 | 0 | 0 | 0 | 6 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
Other chemistry parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Creatinine, Grade 1 | Creatinine, Grade 2 | Creatinine, Grade 3 | Creatinine, Grade 4 | Blood Urea Nitrogen (BUN), Grade 1 | BUN, Grade 2 | BUN, Grade 3 | BUN, Grade 4 | Hypoalbuminemia, Grade 1 | Hypoalbuminemia, Grade 2 | Hypoalbuminemia, Grade 3 | Hypoalbuminemia, Grade 4 | Hyperuricemia, Grade 1 | Hyperuricemia, Grade 2 | Hyperuricemia, Grade 3 | Hyperuricemia, Grade 4 | Hyperglycemia, Grade 1 | Hyperglycemia, Grade 2 | Hyperglycemia, Grade 3 | Hyperglycemia, Grade 4 | Hypoglycemia, Grade 1 | Hypoglycemia, Grade 2 | Hypoglycemia, Grade 3 | Hypoglycemia, Grade 4 | Amylase, Grade 1 | Amylase, Grade 2 | Amylase, Grade 3 | Amylase, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 15 | 1 | 0 | 0 | 5 | 2 | 0 | 0 | 5 | 4 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 2 | 0 | 0 | 2 | 3 | 0 | 0 | 2 | 1 | 0 | 0 |
| Raxibacumab - Single-Dose | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 8 | 1 | 0 | 0 | 36 | 1 | 0 | 0 | 11 | 2 | 0 | 0 | 25 | 5 | 1 | 0 |
Urinaysis parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Proteinuria, Grade 1 | Proteinuria, Grade 2 | Proteinuria, Grade 3 | Proteinuria, Grade 4 | Hematuria, Grade 1 | Hematuria, Grade 2 | Hematuria, Grade 3 | Hematuria, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 9 | 3 | 0 | 0 | 9 | 4 | 0 | 0 |
| Raxibacumab - Double-Dose | 3 | 0 | 0 | 0 | 3 | 2 | 0 | 0 |
| Raxibacumab - Single-Dose | 31 | 9 | 0 | 0 | 17 | 15 | 0 | 0 |
11 reviews available for ciprofloxacin and Bacteremia
| Article | Year |
|---|---|
Role of vancomycin in the treatment of bacteraemia and meningitis caused by Elizabethkingia meningoseptica.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Synergism | 2017 |
Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Biopsy, Large-Core Needle; Ciproflo | 2018 |
[Treatment of vancomycin-resistant enterococcal infections].
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Daptomycin; Denmark; Drug Therapy, Combination; Gr | 2018 |
[Bacteremia caused by ciprofloxacin-resistant Salmonella serotype Kentucky: a case report and the review of literature].
Topics: Anti-Bacterial Agents; Bacteremia; Catheter-Related Infections; Central Venous Catheters; Ciprofloxa | 2016 |
[Vibrio parahaemolyticus bacteremia: case report and literature review].
Topics: Aged, 80 and over; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Humans; Male; Treatment Outcome | 2009 |
Yersinia pseudotuberculosis bloodstream infection and septic arthritis: case report and review of the literature.
Topics: Adult; Anti-Infective Agents; Arthritis, Infectious; Bacteremia; Ciprofloxacin; Humans; Male; Treatm | 2012 |
Campylobacter fetus bacteremia in an immunocompromised patient: case report and review of the literature.
Topics: Adult; Bacteremia; Campylobacter fetus; Campylobacter Infections; Ciprofloxacin; Cytomegalovirus; Fe | 2004 |
[Bacterial infections in liver cirrhosis].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites; | 2007 |
Multifocal cellulitis and monoarticular arthritis as manifestations of Helicobacter cinaedi bacteremia.
Topics: Adult; AIDS-Related Opportunistic Infections; Arthritis, Infectious; Bacteremia; Cellulitis; Child, | 1995 |
Rahnella aquatilis bacteremia in an HIV-infected intravenous drug abuser.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Gram-Ne | 1995 |
Systemic cat scratch disease: a brief case report and review of the literature.
Topics: Adult; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Bartonella henselae; Cat-S | 1998 |
31 trials available for ciprofloxacin and Bacteremia
| Article | Year |
|---|---|
Low rates of antibiotic resistance and infectious mortality in a cohort of high-risk hematology patients: A single center, retrospective analysis of blood stream infection.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Bacterial; Febrile Neutropenia; F | 2017 |
Single-dose versus multiple-dose ciprofloxacin plus metronidazole prophylaxis in transrectal ultrasound-guided biopsy of the prostate: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial | 2014 |
Raxibacumab for the treatment of inhalational anthrax.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anthrax; Anti-Infective Agents; Antibodies, Bac | 2009 |
Reduction in bacteremia rates after rectum sterilization before transrectal, ultrasound-guided prostate biopsy: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, Local; Antibiotic Prophylaxis | 2009 |
Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia.
Topics: Anti-Infective Agents; Area Under Curve; Bacillus; Bacteremia; Ciprofloxacin; Cross-Over Studies; Do | 2010 |
An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Creatinine; Critical Illness; Female; | 2011 |
Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Cefepime; | 2013 |
Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever.
Topics: Adolescent; Adult; Bacteremia; Bone Marrow; Chloramphenicol; Ciprofloxacin; Cytokines; Female; Human | 2003 |
Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin.
Topics: Bacteremia; beta-Lactamases; Ciprofloxacin; Drug Resistance, Bacterial; Female; Humans; Imipenem; Kl | 2004 |
A pilot study of prophylactic ciprofloxacin during delayed intensification in children with acute lymphoblastic leukemia.
Topics: Adolescent; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Child; Child, Preschool; Cipr | 2004 |
Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Anticoagulants; Bacteremia; Blood; | 2006 |
Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial.
Topics: Abscess; Adult; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Double-Blind Method; Drug Resistan | 1995 |
Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole.
Topics: Administration, Oral; Adult; Bacteremia; Blood Platelets; Bone Marrow Transplantation; Cell Count; C | 1995 |
Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
Topics: Adult; Aged; Agranulocytosis; Anti-Infective Agents; Bacteremia; Bacterial Infections; Ciprofloxacin | 1994 |
Single-dose versus 3-day prophylaxis with ciprofloxacin in transurethral surgery. A clinical trial.
Topics: Bacteremia; Bacteriuria; Ciprofloxacin; Drug Administration Schedule; Humans; Male; Postoperative Co | 1993 |
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Aztreonam; Bacteremia; Bacterial Inf | 1993 |
A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Bacterem | 1996 |
Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteremia; Ciprofloxac | 1996 |
Sepsis associated with hematological malignancies: prophylaxis of Pseudomonas aeruginosa sepsis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Bacteremia; Ciprofloxacin; Drug | 1996 |
The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease.
Topics: Abdomen; Adult; Aged; Bacteremia; Ciprofloxacin; Creatine; Dose-Response Relationship, Drug; Female; | 1997 |
A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team.
Topics: Adult; AIDS-Related Opportunistic Infections; Amikacin; Bacteremia; Ciprofloxacin; Clofazimine; Colo | 1998 |
Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group.
Topics: AIDS-Related Opportunistic Infections; Bacteremia; Ciprofloxacin; Clarithromycin; Clofazimine; Drug | 1999 |
Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Ag | 1999 |
Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Can
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Agranulocytosis; Amikacin; Amoxici | 1999 |
Emergence and dissemination of quinolone-resistant Escherichia coli in the community.
Topics: Aged; Animals; Animals, Domestic; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Community-Acquir | 1999 |
Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: A randomized, multicenter, double-blind trial.
Topics: Anti-Infective Agents; Bacteremia; Catheterization, Central Venous; Child; Child, Preschool; Ciprofl | 2000 |
Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010). Canadian HIV Trials Network Protocol 010 Study Group.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Bacteremia; Canada; | 2000 |
Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients.
Topics: Anti-Infective Agents; Bacteremia; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; | 2000 |
Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety.
Topics: Adult; Aged; Bacteremia; Cefuroxime; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Male; | 1992 |
A 7-day course of ciprofloxacin for enteric fever.
Topics: Administration, Oral; Adult; Bacteremia; Ciprofloxacin; Drug Administration Schedule; Female; Humans | 1992 |
Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Amikacin; Anti-Infective Agents; Ba | 1992 |
265 other studies available for ciprofloxacin and Bacteremia
| Article | Year |
|---|---|
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cross Infection; Drug Resistance, B | 2007 |
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cross Infection; Drug Resistance, B | 2007 |
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cross Infection; Drug Resistance, B | 2007 |
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cross Infection; Drug Resistance, B | 2007 |
Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
Topics: Bacteremia; Community-Acquired Infections; Cross Infection; DNA, Bacterial; Drug Resistance, Multipl | 2007 |
Changes in qnr prevalence and fluoroquinolone resistance in clinical isolates of Klebsiella pneumoniae and Enterobacter spp. collected from 1990 to 2005.
Topics: Anti-Infective Agents; Bacteremia; Bacterial Proteins; Ciprofloxacin; Drug Resistance, Bacterial; En | 2007 |
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactams; DNA, Bacterial; Drug Resistance, B | 2007 |
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Drug Resistance, | 2008 |
In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae.
Topics: Bacteremia; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Pyrimidines; Respirator | 2009 |
Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.
Topics: Anti-Bacterial Agents; Bacteremia; Colistin; Cross Infection; Drug Resistance, Bacterial; Humans; Kl | 2010 |
Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamas | 2010 |
Effectiveness and antimicrobial susceptibility profiles during primary antimicrobial prophylaxis for pediatric acute myeloid leukemia.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Bacteremia; Child; Ciprofloxacin; | 2021 |
Introducing the Escalation Antibiogram: A Simple Tool to Inform Changes in Empiric Antimicrobials in the Nonresponding Patient.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Ceftriaxone; Ciprofloxacin; Erta | 2022 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2020.
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2022 |
Intravenous to oral transition of antibiotics for gram-negative bloodstream infection at a University hospital in Thailand: Clinical outcomes and predictors of treatment failure.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Gram-Negative Bacterial Infections; HIV Infections | 2022 |
Haematospirillum jordaniae Cellulitis and Bacteremia.
Topics: Bacteremia; Cellulitis; Ciprofloxacin; Humans; Male; Middle Aged; Rhodospirillaceae | 2022 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP).
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2022 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP).
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2022 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP).
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2022 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP).
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2022 |
Differences in the distribution of pathogens and antimicrobial resistance in bloodstream infections in migrants compared with non-migrants in Denmark.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Community-Acquired Infections; Denmark; Drug Resis | 2023 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP) Bloodstream Infection Annual Report 2022.
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2023 |
Characterization of ESBL-Producing
Topics: Adolescent; Anti-Bacterial Agents; Bacteremia; Carbapenems; Child; Child, Preschool; Ciprofloxacin; | 2019 |
Rapid detection of antibiotic resistance in positive blood cultures by MALDI-TOF MS and an automated and optimized MBT-ASTRA protocol for
Topics: Anti-Bacterial Agents; Bacteremia; Cefotaxime; Ciprofloxacin; Drug Resistance, Bacterial; Escherichi | 2020 |
Elizabethkingia anophelis Infection in Infants, Cambodia, 2012-2018.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Female; Flavobacteriaceae; Flavobacteriaceae Infec | 2020 |
Comparison of two different anti-infectious approaches after high-dose chemotherapy and autologous stem cell transplantation for hematologic malignancies in a 12-year period in British Hospital, Uruguay.
Topics: Adolescent; Adult; Aged; Amikacin; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Prot | 2020 |
Non-typhoidal Salmonella bloodstream infections in Kisantu, DR Congo: Emergence of O5-negative Salmonella Typhimurium and extensive drug resistance.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Bacteremia; Ceftriaxone; Child; Child, Presc | 2020 |
Ciprofloxacin prophylaxis is associated with a lower incidence of gram-negative bacteremia in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Ciprofloxacin; Hematopoietic Stem Cell Tr | 2020 |
Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacteremia; Ciprofloxacin; Disease Models, | 2021 |
Clinical features and outcome of Aeromonas sobria bacteremia in pediatric and adult patients with hematologic malignancies: A single-center retrospective study in Peru.
Topics: Adolescent; Adult; Aeromonas; Aged; Bacteremia; Child; Child, Preschool; Ciprofloxacin; Cross Infect | 2021 |
A small outbreak of Serratia liquefaciens bacteremia due to use of contaminated saline infusion solution for myocardial perfusion scintigraphy.
Topics: Aged; Bacteremia; Ciprofloxacin; Disease Outbreaks; Equipment Contamination; Female; Humans; Male; M | 2017 |
Bacteremia caused by Elizabethkingia meningoseptica in a mechanically ventilated patient successfully treated with imipenem-cilastatin and ciprofloxacin.
Topics: Anti-Bacterial Agents; Bacteremia; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; | 2017 |
A catheter-related bloodstream infection caused by Chryseobacterium indologenes successfully treated with antibiotic-lock rescue therapy.
Topics: Anti-Bacterial Agents; Bacteremia; Catheter-Related Infections; Central Venous Catheters; Child; Chr | 2017 |
Plasmid-Mediated Colistin Resistance Gene mcr-1 in an Escherichia coli ST10 Bloodstream Isolate in the Sultanate of Oman.
Topics: Amikacin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteremia; Ciproflo | 2018 |
Multiple Liver Abscesses with a Skin Pustule due to Chromobacterium violaceum.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Chromobacterium; Ciprofloxacin; Female; Gram-Negative Bacte | 2017 |
Automated direct screening for resistance of Gram-negative blood cultures using the BD Kiestra WorkCell.
Topics: Ampicillin; Anti-Bacterial Agents; Bacteremia; Blood Culture; Ceftriaxone; Ciprofloxacin; Disk Diffu | 2018 |
Non-tuberculous mycobacterium bacteraemia in a pregnant systemic lupus erythematosus (SLE) patient: a case review and pooled case analysis.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Clarithromycin; Female; Humans; Lupus Eryth | 2018 |
Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Carbapenem-Resistant Enterobacteriaceae; Ciprofloxacin; Esc | 2018 |
Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Ciprofloxacin; Controlled Be | 2018 |
Selection of hyperproduction of AmpC and SME-1 in a carbapenem-resistant Serratia marcescens isolate during antibiotic therapy.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cipr | 2018 |
Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Ciprofloxacin; Cohort Stud | 2018 |
In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital.
Topics: Academic Medical Centers; Acinetobacter baumannii; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; | 2017 |
Ciprofloxacin vs. levofloxacin for prophylaxis in recipients of hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremi | 2019 |
Liver abscess with Citrobacter koseri bacteremia.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Breast Neoplasms, Male; Ciprofloxacin; Citroba | 2018 |
Unexpected source of
Topics: Aged, 80 and over; Aneurysm, Infected; Anti-Bacterial Agents; Aortic Aneurysm, Thoracic; Bacteremia; | 2018 |
Bacteremia by Chryseobacterium oranimense, A Colistin-Resistant Gram-Negative Bacilli, in an Immunocompetent Pediatric Patient.
Topics: Anti-Bacterial Agents; Autistic Disorder; Bacteremia; Child; Chryseobacterium; Ciprofloxacin; Colist | 2019 |
Comparison of intravenous and oral definitive antibiotic regimens in hospitalised patients with Gram-negative bacteraemia from a urinary tract infection.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; B | 2019 |
Yersinia pseudotuberculosis bacteraemia: a diagnostic dilemma in the era of MALDI-TOF mass spectrometry.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Typing Techniques; Bacteriophages; Ceftriaxone; C | 2019 |
Septic shock due to Rhodococcus equi in a patient with chronic myelomonocytic leukemia.
Topics: Actinomycetales Infections; Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Diagnosis, Diffe | 2013 |
[Incidence and susceptibility of Campylobacter jejuni in pediatric patients: involvement in bacteremia].
Topics: Adolescent; Anti-Bacterial Agents; Bacteremia; Campylobacter Infections; Campylobacter jejuni; Child | 2013 |
Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremi | 2013 |
Emergency hospital admissions attributable to infective complications of prostate biopsy despite appropriate prophylaxis: need for additional infection prevention strategies?
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; | 2014 |
Multidrug-resistant Escherichia coli bacteremia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistanc | 2013 |
Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis.
Topics: Adult; Aged; Antibiotic Prophylaxis; Bacteremia; Bacteria; Bacterial Infections; Ciprofloxacin; Fema | 2013 |
Bacteremia due to Aeromonas hydrophila in acute lymphoblastic leukemia.
Topics: Acute Disease; Aeromonas hydrophila; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Female; Fever | 2013 |
Microbicidal effects of α- and θ-defensins against antibiotic-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: alpha-Defensins; Amino Acid Sequence; Bacteremia; Bacterial Infections; Ciprofloxacin; Defensins; Dr | 2015 |
Helicobacter canis bacteremia in a renal transplant patient.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Cefuroxime; Ciprofloxacin; DNA, Bacterial; DNA, Ribosomal; | 2014 |
Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations.
Topics: Adolescent; Adult; Aged; Amphotericin B; Anti-Infective Agents; Bacteremia; Candidiasis; Child; Chil | 2014 |
Bloodstream and central line isolates from hematopoietic stem cell transplant recipients: data from a developing country.
Topics: Acyclovir; Adolescent; Adult; Anti-Infective Agents; Bacteremia; Candida albicans; Candidiasis; Cath | 2014 |
Treatment failure due to induction of ciprofloxacin resistance during combination therapy with colistin and ciprofloxacin in multidrug-resistant Pseudomonas aeruginosa bacteraemia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Drug Re | 2014 |
Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacteri | 2014 |
Bacteremia caused by an Acinetobacter junii strain harboring class 1 integron and diverse DNA mobile elements.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Anti-Bacterial Agents; Bacteremia; Catheter-Related | 2014 |
Campylobacter jejuni bacteraemia in a patient presenting with gastroenteritis.
Topics: Administration, Intravenous; Adult; Bacteremia; Campylobacter Infections; Campylobacter jejuni; Cipr | 2014 |
[Bacteriemia due to Mycobacterium canariasense in an oncohematological patient with a long-term central device].
Topics: Aged; Bacteremia; Bacterial Typing Techniques; Catheter-Related Infections; Catheterization, Central | 2014 |
Antimicrobial co-resistance patterns of gram-negative bacilli isolated from bloodstream infections: a longitudinal epidemiological study from 2002-2011.
Topics: Anti-Bacterial Agents; Bacteremia; British Columbia; Ciprofloxacin; Drug Resistance, Bacterial; Ente | 2014 |
Emergence of a KPC-3-Producing Escherichia coli ST69 as a Cause of Bloodstream Infections in Italy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; beta-Lactamases; | 2015 |
Staphylococcus saprophyticus bacteremia after ESWL in an immunocompetent woman.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Female; Humans; Lithotripsy; Microbial Sensitivity | 2015 |
Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 131.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Ciprofloxacin; Comorbidity; Drug Re | 2015 |
Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia.
Topics: Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacteria; Child; Child, Presc | 2015 |
Improved outcome with early rifampicin combination treatment in methicillin-sensitive Staphylococcus aureus bacteraemia with a deep infection focus - a retrospective cohort study.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Cloxacillin; Drug Therapy, Combination; Fema | 2015 |
Bloodstream bacterial infection among outpatient children with acute febrile illness in north-eastern Tanzania.
Topics: Acute Disease; Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Child; Child, Preschool; Chlorampheni | 2015 |
Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Blood Culture; Carbapenem-Resistant | 2017 |
Development of a Pefloxacin Disk Diffusion Method for Detection of Fluoroquinolone-Resistant Salmonella enterica.
Topics: Anti-Bacterial Agents; Bacteremia; Base Sequence; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; | 2015 |
Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Biopsy; Ceftriaxone; Ciprofloxacin; | 2015 |
Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anthrax; Anti-Bacterial Agents; Bacillus ant | 2015 |
Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Bacteremia; Ciprofloxacin; Drug Re | 2015 |
Invasive Salmonella Infections at Multiple Surveillance Sites in the Democratic Republic of the Congo, 2011-2014.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Bacteremia; beta-Lactamases; Child; Ch | 2015 |
Gardnerella vaginalis: An overlooked pathogen in male patients?
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bacteremia; Ceftriaxone; Ciprofloxacin; Drug Resistance, | 2015 |
Mother's Milk as a Source of Enterobacter cloacae Sepsis in a Preterm Infant.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Bottle Feeding; Breast Feeding; Breast Milk Expression; Ca | 2015 |
Clinical characteristics in adult patients with Salmonella bacteremia and analysis of ciprofloxacin-nonsusceptible isolates.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; Base Sequence; beta-Lactamases; | 2015 |
Kingella kingae Sequence Type 25 Causing Endocarditis with Multiple and Severe Cerebral Complications.
Topics: Amoxicillin; Anti-Bacterial Agents; Bacteremia; Cerebrospinal Fluid; Ciprofloxacin; Drug Combination | 2016 |
Antibiotic Susceptibility of Biofilm Cells and Molecular Characterisation of Staphylococcus hominis Isolates from Blood.
Topics: Amidohydrolases; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; Biofilms; Cefoxitin; Chromos | 2015 |
The Emergence of Reduced Ciprofloxacin Susceptibility in Salmonella enterica Causing Bloodstream Infections in Rural Ghana.
Topics: Anti-Bacterial Agents; Bacteremia; Child, Preschool; Ciprofloxacin; Drug Resistance, Multiple, Bacte | 2016 |
Molecular Characterization of Methicillin-Resistant Staphylococcus aureus Bloodstream Isolates in a Turkish University Hospital Between 2002 and 2012.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Typing Techniques; Chromosomes, Bacterial; Ciprofloxaci | 2016 |
Shewanella algae bacteremia from a foot ulcer exposed to seawater during a Caribbean vacation.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Caribbean Region; Ciprofloxacin; Diabetes Mellitus, Type 2; | 2016 |
Ciprofloxacin prophylaxis delays initiation of broad-spectrum antibiotic therapy and reduces the overall use of antimicrobial agents during induction therapy for acute leukaemia: A single-centre study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacterial Infections; Carbapenems | 2016 |
Near-drowning-associated pneumonia with bacteremia caused by coinfection with methicillin-susceptible Staphylococcus aureus and Edwardsiella tarda in a healthy white man: a case report.
Topics: Adult; Bacteremia; Ceftriaxone; Ciprofloxacin; Clindamycin; Coinfection; Edwardsiella tarda; Enterob | 2016 |
Rapid increase in resistance to third generation cephalosporins, imipenem and co-resistance in Klebsiella pneumoniae from isolated from 7,140 blood-cultures (2010-2014) using EARS-Net data in Spain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Bact | 2017 |
Risk factors for hospital-acquired bacteremia due to carbapenem-resistant Pseudomonas aeruginosa in a Colombian hospital.
Topics: Bacteremia; beta-Lactams; Carbapenems; Case-Control Studies; Ciprofloxacin; Drug Resistance, Bacteri | 2016 |
Whole-Genome Sequencing Identifies In Vivo Acquisition of a blaCTX-M-27-Carrying IncFII Transmissible Plasmid as the Cause of Ceftriaxone Treatment Failure for an Invasive Salmonella enterica Serovar Typhimurium Infection.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Ceftriaxone; Ciprofloxacin; Escherichia co | 2016 |
Bacteremia during neutropenic episodes in children undergoing hematopoietic stem cell transplantation with ciprofloxacin and penicillin prophylaxis.
Topics: Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antilymphocyte Serum; Bacteremia; Child; | 2017 |
Extended-Spectrum beta (β)-Lactamases and Antibiogram in Enterobacteriaceae from Clinical and Drinking Water Sources from Bahir Dar City, Ethiopia.
Topics: Adult; Age Factors; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Child, Preschool; Chloramphe | 2016 |
Nocardia Bacteremia and Endocarditis in a Patient With a Sulfa Allergy.
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Drug Hypersensitivity; Dyspnea; Endocard | 2016 |
Antimicrobial susceptibility to azithromycin among Salmonella enterica Typhi and Paratyphi A isolates from India.
Topics: Anti-Bacterial Agents; Azithromycin; Bacteremia; Ciprofloxacin; Drug Resistance, Bacterial; Humans; | 2016 |
Plasmid-mediated quinolone resistance determinants among Gram-negative bacteraemia isolates: a hidden threat.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; | 2017 |
Nanomechanical sensor applied to blood culture pellets: a fast approach to determine the antibiotic susceptibility against agents of bloodstream infections.
Topics: Ampicillin; Anti-Bacterial Agents; Bacteremia; Blood Culture; Ceftriaxone; Ciprofloxacin; Double-Bli | 2017 |
Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Drug T | 2017 |
Bacterial Infections in Children With Acute Myeloid Leukemia Receiving Ciprofloxacin Prophylaxis.
Topics: Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Child; | 2017 |
Ciprofloxacin-resistant and extended-spectrum β-lactamase-producing Escherichia coli ST410 strain carrying the mcr-1 gene associated with bloodstream infection.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Brazil; Ciprofloxacin; Drug Resistance, Bacteria | 2017 |
Bacillus cereus nosocomial infection from reused towels in Japan.
Topics: Adult; Aged, 80 and over; Anti-Bacterial Agents; Bacillus cereus; Bacteremia; Bacterial Toxins; Bedd | 2008 |
Modification in prescribing practices for third-generation cephalosporins and ciprofloxacin is associated with a reduction in meticillin-resistant Staphylococcus aureus bacteraemia rate.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Ciprofloxacin; Drug Prescriptions; Hospitals; Hum | 2008 |
Virulence factors and biofilm production among Escherichia coli strains causing bacteraemia of urinary tract origin.
Topics: Bacteremia; Biofilms; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Escherichia coli; Urinary | 2008 |
Antimicrobial resistance among Escherichia coli strains isolated from healthy and septicemic chickens.
Topics: Animals; Anti-Infective Agents; Bacteremia; Case-Control Studies; Chickens; Ciprofloxacin; Drug Resi | 2007 |
[Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Bacteriological Techniques; Ceftazidime; Ciprofloxacin; | 2009 |
[Non necrotizing bacterial cellulitis and bacteriemia due to Shewanella putrefaciens].
Topics: Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Ceftriaxone; Cellulitis | 2009 |
Antibiotic prophylaxis in gastrointestinal endoscopy.
Topics: Antibiotic Prophylaxis; Bacteremia; Ciprofloxacin; Endocarditis, Bacterial; Endoscopy, Gastrointesti | 2009 |
Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistanc | 2009 |
Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus infections in children with cancer.
Topics: Adolescent; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; Bacterial Toxins; Child; Child, P | 2009 |
Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Erythromycin; Glycopeptides; Hospitals, Teaching; | 2009 |
Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE.
Topics: Acetamides; Anti-Bacterial Agents; Bacteremia; Case-Control Studies; Ciprofloxacin; Daptomycin; Ente | 2010 |
Spondylodiscitis and an aortic aneurysm due to Campylobacter coli.
Topics: Aged; Anti-Bacterial Agents; Aortic Aneurysm, Abdominal; Bacteremia; Campylobacter coli; Campylobact | 2010 |
[Shigella bacteremia dysentery in an adult].
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Dysentery, Bacillary; Female; Humans; Microb | 2010 |
Bilateral necrotising fasciitis of the ocular adnexa secondary to Pseudomonas aeruginosa septicaemia in a HIV-positive child.
Topics: Anti-Bacterial Agents; Bacteremia; CD4 Lymphocyte Count; Ceftazidime; Ciprofloxacin; Drug Therapy, C | 2010 |
Hospital-acquired pneumonia and bacteremia caused by Legionella pneumophila in an immunocompromised patient.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftazidime; Ciprofloxacin; Clindamycin; Cross Infection; Female; | 2010 |
A novel antibiotic based long-term model of ovine smoke inhalation injury and septic shock.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Disease Models, Animal; Female; Nitric Ox | 2010 |
Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland.
Topics: Acute Disease; Aged; Anti-Infective Agents, Urinary; Bacteremia; Bacteriuria; Ciprofloxacin; Cross-S | 2010 |
Bordetella bronchiseptica bacteremia in a patient with AIDS.
Topics: Adult; AIDS-Associated Nephropathy; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Ba | 2010 |
[A case of Salmonella enterica serovar typhi with decreased susceptibility to ciprofloxacin].
Topics: Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; | 2010 |
Bacteraemia with pleural effusions complicating typhoid fever caused by high-level ciprofloxacin-resistant Salmonella enterica serotype Typhi.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; Ceftriaxone; Child; | 2010 |
Colonisation with Escherichia coli resistant to "critically important" antibiotics: a high risk for international travellers.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Australia; Bacteremia; Carrier State; Ciprofloxacin; | 2010 |
Biofilm production, use of intravascular indwelling catheters and inappropriate antimicrobial therapy as predictors of fatality in Chryseobacterium meningosepticum bacteraemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Biofilms; Catheters, | 2010 |
Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Cohort Studies; Community-Acquired Infection | 2011 |
Melioidosis presenting as sepsis syndrome: a case report.
Topics: Anti-Bacterial Agents; Bacteremia; Burkholderia pseudomallei; Cefepime; Ceftazidime; Cephalosporins; | 2011 |
Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Proteus mirabilis bacteremia.
Topics: Adult; Aged; Anti-Infective Agents; Bacteremia; beta-Lactamases; Ciprofloxacin; Drug Resistance, Bac | 2011 |
Nonpigmented Chromobacterium violaceum bacteremic cellulitis after fish bite.
Topics: Anti-Bacterial Agents; Bacteremia; Bacteriological Techniques; Bites and Stings; Cellulitis; Chromob | 2011 |
Comamonas testosteroni infection in Taiwan: Reported two cases and literature review.
Topics: Aged; Alcoholism; Anti-Bacterial Agents; Bacteremia; Carcinoma, Hepatocellular; Cellulitis; Cephalos | 2011 |
Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia.
Topics: Acetamides; Bacteremia; Catheter-Related Infections; Ciprofloxacin; Cross Infection; Daptomycin; Dru | 2011 |
Antimicrobial resistance trends in blood culture positive Salmonella Typhi isolates from Pondicherry, India, 2005-2009.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Blood; Child; Child, Preschool; Ciproflo | 2012 |
Ciprofloxacin in critically ill children.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Infections; Child, Preschool; Ciprofloxacin; Critical C | 2011 |
Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacteremia; Child; Child, Preschool; Ciprofloxacin; Deh | 2011 |
Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes.
Topics: Adaptation, Biological; Anti-Bacterial Agents; Bacteremia; Burkholderia; Burkholderia Infections; Ci | 2011 |
[Endogenous endophthalmitis as a first clinical manifestation of Klebsiella sepsis. The importance of an early diagnosis].
Topics: Anti-Bacterial Agents; Bacteremia; Chorioretinitis; Choroid Hemorrhage; Ciprofloxacin; Combined Moda | 2011 |
Clinical consequences of increased ciprofloxacin and gentamicin resistance in patients with Escherichia coli bacteraemia in the Netherlands.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Case-Control Studies; | 2012 |
[Septic arthritis of hip due to Salmonella Typhi in a patient with multiple sclerosis].
Topics: Administration, Oral; Adult; Anti-Infective Agents; Arthritis, Infectious; Bacteremia; Bursitis; Cip | 2012 |
Tigecycline therapy for bacteremia and aortitis caused by Salmonella enterica serotype Choleraesuis: A case report.
Topics: Aged; Anti-Bacterial Agents; Aortitis; Bacteremia; Ciprofloxacin; Humans; Male; Minocycline; Salmone | 2016 |
An unusual dual infection with Salmonella bredeney, including bacteraemia, and enterohaemorrhagic Escherichia coli O157 that posed a therapeutic dilemma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Coinfection; Enterohemorrhagic Escher | 2012 |
Pseudomembranous colitis and bacteremia in an immune competent patient associated with a rare specie of Clostridium (C. ramosum).
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteremia; Ciprofloxaci | 2012 |
Investigation of mutation distribution in DNA gyrase and topoisomerase IV genes in ciprofloxacin-non-susceptible Enterobacteriaceae isolated from blood cultures in a tertiary care university hospital in South Korea, 2005-2010.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; | 2013 |
Azithromycin and ciprofloxacin resistance in Salmonella bloodstream infections in Cambodian adults.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Bacteremia; Cambodia; Child; Ciproflox | 2012 |
Decline in ciprofloxacin-resistant Salmonella enterica Serovar Choleraesuis in Taiwan, 2001-2011.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Bacteri | 2013 |
Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance.
Topics: Anti-Bacterial Agents; Bacteremia; Cancer Care Facilities; Ciprofloxacin; Drug Resistance, Bacterial | 2013 |
Shigella flexneri bacteraemia in an immunocompetent male treated with oral ciprofloxacin.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Dysentery, Bacillary; | 2002 |
[Epidemiology of septicaemia pathogens].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Austria; Bacteremia; Bacteria; Ciprofloxacin; Drug Res | 2002 |
Yersinia pseudotuberculosis bacteraemia in a kidney transplant patient.
Topics: Anti-Infective Agents; Bacteremia; Ciprofloxacin; Cyclosporine; Humans; Immunosuppressive Agents; Ki | 2002 |
Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Ciprofloxacin | 2003 |
[Bacteremia due to Escherichia coli: epidemiological analysis and sensitivity to antibiotics in a county hospital].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Cross Infection; Drug Resis | 2003 |
Two widely disseminated strains of Enterococcus faecalis highly resistant to gentamicin and ciprofloxacin from bacteraemias in the UK and Ireland.
Topics: Bacteremia; Ciprofloxacin; Drug Resistance, Bacterial; Enterococcus faecalis; Gentamicins; Humans; I | 2003 |
Cutaneous infection caused by Salmonella typhi.
Topics: Adult; Bacteremia; Biopsy, Needle; Ciprofloxacin; Endemic Diseases; Female; Follow-Up Studies; Human | 2003 |
[Community-acquired Pseudomonas aeruginosa bacteremic pneumonia in a "healthy" subject].
Topics: Adult; Anti-Infective Agents; Bacteremia; Bronchoalveolar Lavage; Ciprofloxacin; Community-Acquired | 2003 |
Salmonella bloodstream infections: report from the SENTRY Antimicrobial Surveillance Program (1997-2001).
Topics: Bacteremia; Ciprofloxacin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensi | 2003 |
Ciprofloxacin-resistant Escherichia coli from bacteraemias in England; increasingly prevalent and mostly from men.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Child; Child, Preschool; Ciprofloxacin; | 2003 |
Gram-negative bacteraemia (GNB) after 428 unrelated donor bone marrow transplants (UD-BMT): risk factors, prophylaxis, therapy and outcome.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Bacteremia; Bone Marrow Transplantation; Case-Control Stu | 2004 |
Sternoclavicular joint infection in an adult without predisposing risk factors.
Topics: Arthritis, Infectious; Bacteremia; Ceftriaxone; Ciprofloxacin; Drug Therapy, Combination; Humans; Ma | 2003 |
Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation.
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Female; Fluoroquinolones; Hematopoi | 2004 |
Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year.
Topics: Analysis of Variance; Bacteremia; Case-Control Studies; Child Development; Ciprofloxacin; Dose-Respo | 2004 |
Peritoneal dialysis-related peritonitis with bacteraemia due to Erysipelothrix rhusiopathiae.
Topics: Anti-Infective Agents; Bacteremia; Ciprofloxacin; Erysipelothrix; Erysipelothrix Infections; Humans; | 2004 |
Virulence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in vitro and in vivo.
Topics: Animals; Bacteremia; beta-Lactamases; Ceftazidime; Cephalosporins; Cilastatin; Ciprofloxacin; Drug T | 2004 |
Risk Factors for Ciprofloxacin Resistance in Bloodstream Infections Due to Extended-Spectrum beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteremia; beta-Lactamases; Case-Control Studies; Cipro | 2004 |
Cardiobacterium hominis endocarditis associated with very severe thrombocytopenia and platelet autoantibodies.
Topics: Ampicillin; Antigens, Human Platelet; Aortic Valve Stenosis; Autoantibodies; Autoimmune Diseases; Ba | 2004 |
Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series.
Topics: Anti-Infective Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Humans; Micr | 2004 |
Use of simulated blood cultures for antibiotic effect on time to detection of the two blood culture systems BacT/ALERT and BACTEC 9240.
Topics: Ampicillin; Anti-Bacterial Agents; Bacteremia; Bacteria; Bacteriological Techniques; Blood; Cefotaxi | 2004 |
Community-acquired methicillin-resistant Staphylococcus aureus prostatic abscess.
Topics: Abscess; Adult; Bacteremia; Ciprofloxacin; Combined Modality Therapy; Community-Acquired Infections; | 2004 |
Five cases of non-typhoidal Salmonella endovascular infection.
Topics: Aged; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Humans; Male; Middle Aged; Salmonella enteri | 2004 |
Nosocomial bloodstream infections with Burkholderia stabilis.
Topics: Adolescent; Adult; Aged; Bacteremia; Bacterial Typing Techniques; Burkholderia; Burkholderia Infecti | 2005 |
A new therapeutic challenge for old pathogens: community-acquired invasive infections caused by ceftriaxone- and ciprofloxacin-resistant Salmonella enterica serotype choleraesuis.
Topics: Adult; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Ceftriaxone; Ciproflox | 2005 |
Clinical epidemiology of ciprofloxacin resistance and its relationship to broad-spectrum cephalosporin resistance in bloodstream infections caused by Enterobacter species.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacteremia; Case-Control Studies; Cephalosporins; Ci | 2005 |
Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Bacteria | 2005 |
Bacteremia among Kenyan Children.
Topics: Bacteremia; Cephalosporins; Ciprofloxacin; Fever of Unknown Origin; Ghana; Humans; Microbial Sensiti | 2005 |
Influence of ciprofloxacin resistance on risk factors for endovascular infection in patients with infection due to group C nontyphoid salmonellae.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteremia; Ciprofloxacin; Drug Resistance, Bacterial; F | 2005 |
Optimization of empirical antibiotic selection for suspected Gram-negative bacteraemia in the emergency department.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Child; Ciprofloxacin; Diabetes Co | 2005 |
In vitro activity of three different antimicrobial agents against ESBL producing Escherichia coli and Klebsiella pneumoniae blood isolates.
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Blood; Ciprofloxacin; Drug Resistance, | 2005 |
Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres.
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Ceftazidime; Child; Ciprofloxacin; Drug Resistance, Mul | 2005 |
Infections of febrile neutropenic patients in malignant hematological diseases (second study period).
Topics: Antibiotic Prophylaxis; Antineoplastic Agents; Bacteremia; Bacterial Infections; Ciprofloxacin; Fema | 2005 |
Recurrent infections caused by cefotaxime- and ciprofloxacin-resistant Salmonella enterica serotype choleraesuis treated successfully with imipenem.
Topics: Anti-Bacterial Agents; Bacteremia; Cefotaxime; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; | 2005 |
Multiple spleen and liver abscesses due to Yersinia enterocolitica septicemia in a child with congenital sideroblastic anemia.
Topics: Anemia, Sideroblastic; Anti-Bacterial Agents; Bacteremia; Child, Preschool; Ciprofloxacin; Humans; I | 2005 |
RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Biofilms; Catheterization, Central Venous; Catheters, In | 2006 |
First recurrent infection with vancomycin-resistant enterococcus from Turkey.
Topics: Anti-Bacterial Agents; Bacteremia; Child, Preschool; Ciprofloxacin; Enterococcus faecium; Female; Gr | 2006 |
First case of febrile bacteremia due to a wild type and small-colony variant of Escherichia coli.
Topics: Adult; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Escherichia coli; Escherichia coli Infectio | 2006 |
Aeromonas veronii biovar sobria bacteraemia with septic arthritis confirmed by 16S rDNA PCR in an immunocompetent adult.
Topics: Aeromonas; Aged, 80 and over; Anti-Infective Agents; Arthritis, Infectious; Bacteremia; Ciprofloxaci | 2006 |
Bacteraemia due to ciprofloxacin-resistant Salmonella enterica serotype Choleraesuis in adult patients at a university hospital in Taiwan, 1996-2004.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Drug R | 2006 |
Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Colistin; Drug Resistance, Bacterial; Gram-Negativ | 2006 |
Bacteraemic pneumonia caused by Neisseria lactamica with reduced susceptibility to penicillin and ciprofloxacin in an adult with liver cirrhosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Base Sequence; Ceftriaxone; Ciprofl | 2006 |
Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy.
Topics: Anti-Bacterial Agents; Anticoagulants; Bacteremia; Catheterization, Central Venous; Catheters, Indwe | 2006 |
Post-ERCP bacteremia caused by Alcaligenes xylosoxidans in a patient with pancreas cancer.
Topics: Aged; Alcaligenes; Anti-Infective Agents; Bacteremia; Cholangiopancreatography, Endoscopic Retrograd | 2006 |
Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; APACHE; Bacteremia; Cephalosporins; Ciprofloxacin; Commu | 2006 |
Cefotaxime-ciprofloxacin combination therapy for nontyphoid Salmonella bacteremia and paravertebral abscess after failure of monotherapy.
Topics: Abscess; Anti-Bacterial Agents; Bacteremia; Cefpodoxime; Ceftizoxime; Ciprofloxacin; Drug Therapy, C | 2006 |
Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; | 2006 |
Ciprofloxacin treatment failure in a case of typhoid fever caused by Salmonella enterica serotype Paratyphi A with reduced susceptibility to ciprofloxacin.
Topics: Adolescent; Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacteria | 2007 |
Drug-resistant nontyphoidal Salmonella bacteremia, Thailand.
Topics: Anti-Infective Agents; Bacteremia; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacterial; Humans; M | 2007 |
Escherichia vulneris as a cause of bacteremia in a patient with chronic lymphocytic leukemia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Drug Therapy, Combination; Enterobacteriacea | 2008 |
Gas-forming splenic abscess due to Salmonella enterica serotype Enteritidis in a chronically hemodialyzed patient.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Ciprofloxacin; Humans; Male; Midd | 2007 |
Community-acquired versus nosocomial Klebsiella pneumonia bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Ciprofloxacin; Community-Acquired Infections; Cro | 2007 |
Identification and control of an outbreak of ciprofloxacin-susceptible EMRSA-15 on a neonatal unit.
Topics: Abscess; Anti-Bacterial Agents; Bacteremia; Bacterial Typing Techniques; Bacteriological Techniques; | 2007 |
Periorbital necrotizing fasciitis.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Breast Neoplasms; | 2007 |
[Clinical cases in Medical Mycology. Case No. 29].
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Arthritis, Infectious; Bacteremia; Ciprofloxacin; C | 2007 |
Biofilm formation in Acinetobacter baumannii: associated features and clinical implications.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Bacteremia; B | 2008 |
Aeromonas hydrophila bacteraemia and portal pyaemia.
Topics: Aeromonas hydrophila; Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Gram-Negative Bacteria | 2008 |
Use of gas-liquid chromatography for subgrouping coagulase-negative staphylococci during a nosocomial sepsis outbreak.
Topics: Anti-Infective Agents; Bacteremia; Chromatography, Gas; Ciprofloxacin; Cluster Analysis; Coagulase; | 1995 |
Autoimmune haemolytic anaemia associated with ciprofloxacin.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Bacteremia; Ciprofloxacin; Diclofenac; Female; Humans; Osteomye | 1995 |
Recurrent Salmonella enteritidis sepsis and hepatic tuberculosis.
Topics: Adult; Anti-Infective Agents; Bacteremia; Ceftriaxone; Cephalosporins; Ciprofloxacin; Drug Resistanc | 1995 |
A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens.
Topics: Anti-Infective Agents; Bacteremia; Bacteria; Bacteriuria; Cefotaxime; Ceftazidime; Cefuroxime; Cepha | 1994 |
Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections.
Topics: Adult; Aged; Bacteremia; Case-Control Studies; Ciprofloxacin; Drug Resistance, Microbial; Escherichi | 1995 |
Concurrent falciparum malaria and Salmonella bacteremia in travelers: report of two cases.
Topics: Adult; Bacteremia; Ceftriaxone; Ciprofloxacin; Follow-Up Studies; Humans; Malaria, Falciparum; Male; | 1995 |
Recrudescence and relapse of meningococcal meningitis and septicaemia.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacteremia; Child, Preschool; Chloramphenicol; Ciproflo | 1995 |
Campylobacter jejuni arthritis in secondary amyloidosis.
Topics: Agammaglobulinemia; Aged; Amyloidosis; Arthritis, Infectious; Arthritis, Rheumatoid; Bacteremia; Cam | 1995 |
Vibrio vulnificus septicemia in a patient with liver cirrhosis.
Topics: Animals; Bacteremia; Brachyura; Ceftazidime; Ciprofloxacin; Drug Therapy, Combination; Female; Hepat | 1994 |
Prevention of bacteraemia by systemic ciprofloxacin treatment in rat cytomegalovirus-infected immunocompromised rats.
Topics: Animals; Bacteremia; Ciprofloxacin; Cytomegalovirus Infections; Gram-Negative Aerobic Bacteria; Gram | 1994 |
Reduction in serum concentrations of ciprofloxacin after administration of ursodiol to a patient with hepatobiliary disease.
Topics: Bacteremia; Biliary Tract Diseases; Ciprofloxacin; Drug Interactions; Humans; Klebsiella Infections; | 1994 |
[Bacteremia caused by quinolone-resistant Campylobacter jejuni in a patient with HIV infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Bacteremia; Campylobacter Infec | 1994 |
Pseudomonas aeruginosa bacteraemia in a dog.
Topics: Animals; Bacteremia; Ciprofloxacin; Dog Diseases; Dogs; Male; Microbiological Techniques; Pseudomona | 1994 |
Streptococcus sanguis bacteremia during ciprofloxacin therapy of a diabetic foot ulcer.
Topics: Bacteremia; Ciprofloxacin; Clindamycin; Diabetes Mellitus, Type 1; Diabetic Foot; Drug Resistance, M | 1994 |
Campylobacter jejuni bacteremia and Guillain-Barré syndrome in a patient with GVHD after allogeneic BMT.
Topics: Bacteremia; Bone Marrow Transplantation; Campylobacter Infections; Campylobacter jejuni; Ciprofloxac | 1994 |
[Evolution of fluoroquinolone sensitivity in Staphylococcus aureus isolated from hemocultures in a general hospital].
Topics: Bacteremia; Blood; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Hospitals, General; H | 1993 |
Endocarditis after ciprofloxacin therapy for enterococcal pyelonephritis with bacteremia.
Topics: Aged; Bacteremia; Ciprofloxacin; Drug Therapy, Combination; Endocarditis, Bacterial; Enterococcus fa | 1993 |
Evaluation of penicillin G in the prevention of streptococcal septicaemia in patients with acute myeloid leukaemia undergoing cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bacteremia; Ciprofloxacin; Humans; Leukemia, Myeloid, Acute; Mid | 1993 |
Oral ciprofloxacin for treatment of severe infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacteremia; Bacterial Infections; Ciprofloxaci | 1993 |
Successful treatment of haemodialysis catheter-related sepsis without catheter removal.
Topics: Adult; Aged; Aged, 80 and over; Bacteremia; Catheterization, Central Venous; Catheters, Indwelling; | 1993 |
Prevention of recurrent central venous catheter infections with a novel flush solution in a patient on long-term hemodialysis.
Topics: Bacteremia; Catheterization, Central Venous; Child, Preschool; Ciprofloxacin; Drug Therapy, Combinat | 1993 |
Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis.
Topics: Animals; Antibodies, Monoclonal; Bacteremia; Ciprofloxacin; Combined Modality Therapy; Endotoxins; F | 1993 |
Oral ciprofloxacin therapy for Bacillus cereus wound infection and bacteremia.
Topics: Administration, Oral; Adult; Bacillus cereus; Bacteremia; Ciprofloxacin; Humans; Male; Wound Infecti | 1993 |
Prosthetic hip infection and bacteremia due to Campylobacter jejuni in a patient with AIDS.
Topics: AIDS-Related Opportunistic Infections; Bacteremia; Campylobacter Infections; Campylobacter jejuni; C | 1993 |
Trends in gram-positive bloodstream organism resistance: a seven-year audit of five glycopeptides and other drugs at a large university hospital.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Hospital | 1993 |
Bacteremic necrotizing fasciitis due to Flavobacterium odoratum.
Topics: Aged; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Multiple; Fasciitis, Necrot | 1995 |
Impact of different classes antimicrobial agents on plasma endotoxin activity.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Blood Pressure; Cefotaxime; Cepha | 1996 |
Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients.
Topics: Anti-Infective Agents; Bacteremia; Bacterial Outer Membrane Proteins; Ceftazidime; Cephalosporins; C | 1996 |
Antibiotic-resistant endocarditis in a hemodialysis patient.
Topics: Ampicillin; Bacteremia; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug T | 1996 |
Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue.
Topics: Ambulatory Care; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy | 1996 |
Mycotic aneurysm due to non-typhi salmonella: report of 16 cases.
Topics: Aged; Ampicillin; Aneurysm, Infected; Anti-Bacterial Agents; Arteriosclerosis; Bacteremia; Cefazolin | 1996 |
In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Bacteremia; Catheterizati | 1996 |
Antimicrobial susceptibilities of blood culture isolates obtained before and after the introduction of ciprofloxacin.
Topics: Acinetobacter; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Citrobacter freundii; Drug Resistan | 1997 |
Antibiotic prophylaxis in gastrointestinal endoscopy: a report by a Working Party for the British Society of Gastroenterology Endoscopy Committee.
Topics: Administration, Oral; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophyla | 1997 |
Endogenous Ochrobactrum anthropi endophthalmitis.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Catheterization, Central Venous; Cat | 1997 |
In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Female; Levofloxaci | 1996 |
Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteremia; Ceftazidime; Cephalos | 1997 |
Campylobacter jejuni bacteremia in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: comparison of clinical features and review.
Topics: Adult; Aged; Bacteremia; Campylobacter Infections; Campylobacter jejuni; Ciprofloxacin; Drug Resista | 1998 |
Haemophilus aphrophilus bacteraemia complicated with vertebral osteomyelitis and spinal epidural abscess in a patient with liver cirrhosis.
Topics: Abscess; Aged; Bacteremia; Cefotaxime; Ciprofloxacin; Epidural Space; Female; Haemophilus; Haemophil | 1997 |
The influence of the SOS response on the activity of 4-quinolones and zidovudine against some strains of Enterobacteria.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Infective Agents; Bacteremia; Ciproflox | 1998 |
Cellulitis caused by Citrobacter diversus in a patient with multiple myeloma.
Topics: Anti-Infective Agents; Bacteremia; Cellulitis; Ciprofloxacin; Citrobacter; Diagnosis, Differential; | 1998 |
Antibiotic resistance in Escherichia coli isolated from blood and cerebrospinal fluid: a 6-year study of isolates from patients in England and Wales.
Topics: Ampicillin Resistance; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Cerebrospinal Fluid | 1997 |
A case of Plesiomonas shigelloides cellulitis and bacteraemia from northern Europe.
Topics: Aged; Anti-Infective Agents; Bacteremia; Cellulitis; Ciprofloxacin; Europe; Gram-Negative Bacterial | 1997 |
Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Bacteremia; Ciprofl | 1998 |
Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals.
Topics: Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Com | 1998 |
Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy.
Topics: Adult; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Hematologic N | 1999 |
Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amoxicillin; Anti-HIV Agents; Anti-Infective Agents; Bact | 1999 |
Fatal Clostridium sordellii ischio-rectal abscess with septicaemia complicating ultrasound-guided transrectal prostate biopsy.
Topics: Abscess; Adenocarcinoma; Aged; Ampicillin; Anti-Infective Agents; Bacteremia; Biopsy; Ciprofloxacin; | 1999 |
Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.
Topics: Acute Kidney Injury; Administration, Cutaneous; Animals; Anti-Infective Agents; Bacteremia; Ciproflo | 1999 |
Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis.
Topics: Adult; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacteremia; Ciprofloxac | 1999 |
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Fluoroquinol | 2000 |
Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.
Topics: Anti-Infective Agents; Bacteremia; beta-Lactamases; Ciprofloxacin; Cross Infection; Drug Resistance, | 2000 |
Helicobacter cinaedi septic arthritis and bacteremia in an immunocompetent patient.
Topics: Adult; Anti-Infective Agents; Arthritis, Infectious; Bacteremia; Ciprofloxacin; Helicobacter; Helico | 2000 |
Increased incidence of bacteraemia due to viridans streptococci in an unselected population of patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Antibiotic Prophylaxis; | 2000 |
Non-serogroup O:1 Vibrio cholerae bacteremia and cerebritis.
Topics: Adult; Anti-Infective Agents; Bacteremia; Cefotaxime; Cephalosporins; Cholera; Ciprofloxacin; Humans | 2001 |
Risk of recurrent non-typhoid Salmonella bacteraemia after early discontinuation of ciprofloxacin as secondary prophylaxis in AIDS patients in the era of highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Anti-Infecti | 2001 |
Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Microbial; | 2001 |
Quinolone resistance in neutropenic patients: the effect of prescribing policy in the UK and Pakistan.
Topics: Anti-Infective Agents; Bacteremia; Ciprofloxacin; Drug and Narcotic Control; Drug Prescriptions; Dru | 2001 |
Catheter-related bacteremia due to Lactobacillus rhamnosus in a single-lung transplant recipient.
Topics: Adult; Anti-Infective Agents; Bacteremia; Catheterization; Ciprofloxacin; Equipment Contamination; G | 2001 |
[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Drug Resistance; Drug Resistance, M | 2001 |
Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999.
Topics: Bacteremia; Ciprofloxacin; Drug Resistance, Bacterial; Drug Utilization; England; Enterobacteriaceae | 2002 |
Active systemic anthrax infection or lingering anthrax infection of cerebrospinal compartment?
Topics: Anthrax; Bacillus anthracis; Bacteremia; Cerebrospinal Fluid; Ciprofloxacin; Humans; Prognosis; Seve | 2002 |
Group B streptococcal bacteremia in an adult: a case report from India.
Topics: Adult; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Female; Humans; India; Streptococcal Infect | 2001 |
Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amikacin; Bacteremia; Cause of Death; Ciprofloxacin; Clar | 1992 |
Bordetella bronchiseptica pneumonia and bacteremia following bone marrow transplantation.
Topics: Adult; Bacteremia; Bone Marrow Transplantation; Bordetella bronchiseptica; Bordetella Infections; Ci | 1992 |
Occurrence of bacteremia in hematologic patients.
Topics: Adolescent; Adult; Aged; Bacteremia; Bone Marrow Transplantation; Catheterization; Ciprofloxacin; Fe | 1992 |
[In vitro activity of various antibiotic agents against gram-negative nosocomial bacteremia pathogens].
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Cross Infection; Gram-Negative Bacteria; | 1992 |
Bacteremia due to Campylobacter cinaedi in a patient infected with the human immunodeficiency virus.
Topics: Adult; Bacteremia; Campylobacter Infections; Ciprofloxacin; HIV Infections; Humans; Male | 1992 |
[Escherichia coli bacteremia resistant to ciprofloxacin].
Topics: Bacteremia; Bacteriuria; Ciprofloxacin; Drug Resistance, Microbial; Escherichia coli Infections; Hum | 1991 |
An assessment of the efficacy of antimicrobial prophylaxis in bone marrow autografts.
Topics: Adolescent; Adult; Amphotericin B; Bacteremia; Bacterial Infections; Bone Marrow Transplantation; Ci | 1991 |
[Transitory bacteremia caused by Neisseria meningitidis group B with an intermediate sensitivity to penicillin].
Topics: Bacteremia; Ceftriaxone; Ciprofloxacin; Female; Humans; Middle Aged; Neisseria meningitidis; Neisser | 1991 |
Impact of the duration of infection on the activity of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.
Topics: Animals; Bacteremia; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Administration Schedul | 1991 |
Quinolone therapy in the prevention of mortality after irradiation.
Topics: Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Cobalt Radioisotopes; Female; Gamma Rays; | 1991 |
[Neutropenia caused by ciprofloxacin and Escherichia coli bacteremia. Bone marrow examination].
Topics: Bacteremia; Bone Marrow Examination; Ciprofloxacin; Escherichia coli Infections; Humans; Neutropenia | 1991 |